Development and Applications of Computational Protein Design by Choi, Eun Jung
Development and Applications of Computational Protein Design
Thesis by
Eun Jung Choi
In Partial Fulfillment of the Requirements
for the Degree of
Doctor of Philosophy
California Institute of Technology
Pasadena, California
2006
(Defended May 26, 2006)
ii
© 2006
Eun Jung Choi
All Rights Reserved
iii
Acknowledgements
I would like to thank my advisor, Dr. Stephen Mayo, for his support throughout my
graduate studies. He is a brilliant scientist, and during my stay in his lab, I learned a lot from him.
I am grateful for the opportunity I had in learning about the exciting field of computational
protein design.
My committee members, Dr. Pamela Bjorkman, Dr. David Chan and Dr. Bill Goddard,
always gave me helpful advice at my annual committee meetings. They cared not only about my
research, but also about my long-term goals. I always looked forward to these meetings.
I thank everyone in the Mayo lab, Alex, Barry, Ben, Christina, Dan, Darryl, Deepshika,
Eric, Geoff, Heidi, Jennifer, JJ, Julia, Karin, Kyle, Oscar, Mary, Matthew, Peter, Possu, Premal,
Sarah, Scott, Shannon, Shira, Tom, and Welison for providing a stimulating but comfortable
research environment. Needless to say, Cynthia and Rhonda are the two most indispensable
people in the lab. Marie spent endless hours editing my papers and this thesis would not have
seen the light of day were it not for her efforts. Jessica M. deserves special mention because it
was her fabulous idea to collaborate together. It was a pleasure working with her.
 I owe a lot to my valuable friends whom I was lucky to have met during my stay at
Caltech. Hyun Jee, In Jung, Jessica E., Ji Young, Keum Joo, Kyung Ah, Mi Sook, Sarina and all
of the other people, both past and present, who were always there for me, thank you so much. I
would especially like to thank Caglar for his endless capacity to help on anything and everything.
Ann Marie, Daphne and Frosso, thanks for being such good housemates.
And last, but not the least, I thank my family, my parents and my sister. It is impossible
to express the gratitude I feel for the sacrifice and support my mom and dad have shown me
throughout the years. And thank you Eun Kyong for flying to the U.S. multiple times to see me.
iv
Abstract
Success in computational design of proteins requires a good understanding of the
physical properties that determine the protein structure. However, computational protein
design also provides us the opportunities to test and improve our current knowledge of
protein structure. In our lab, the “protein design cycle” is used to improve the energy
function and increase our knowledge of protein chemistry. This strategy utilizes a cyclic
protocol where first, a modification that is predicted to improve the result is applied to the
energy function. Next, proteins are simulated using this modified function. These
molecules are then synthesized and analyzed to see if our simulation results correlate
with the physical properties of the molecules. The new knowledge from the analysis is
incorporated into the next design in the form of a new modification and the whole cycle
starts again. Using this technique, an energy function highly successful in designing
protein stability has been acquired in our lab.
A similar approach was used to determine whether the introduction of a backbone
entropy term allows us to incorporate proline into the pool of amino acids we consider in
designs. Using ORBIT, several proline mutants of protein G were simulated and
synthesized. The correlation between the experimental results and computational results
was analyzed. From this analysis, we learned that the entropic benefit of a proline
mutation is usually small compared to the enthalpic disadvantages. However, including a
backbone entropy term did increase the correlation between the rank order of the
experimental stabilities and computational energies.
The ultimate test of our protein design protocol is its application to biological
systems of interest. We have applied ORBIT to three different design problems,
vincreasing the affinity of peptide-protein interaction of TRAF6, the elimination of
disulfide bonds for biosensor design and enhancement of solubility and stability of an
anti-htt antibody fragment. The results provided here show that protein design protocol is
a fast and efficient way to manipulate and study biological systems.
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1Chapter 1
Introduction
2The idea of protein design debuted in the early 1980s (Drexler 1981; Pabo 1983).
The protein design problem, which is the search for an amino acid sequence that folds
into the desired structure, was thought of as the inverse of the protein folding problem,
which aims to find the correct fold for a given amino acid sequence. Unlike the protein
folding problem where there is a single solution fold per sequence, multiple solution
sequences can be found for each target fold in the protein design problem (Figure 1).
Assisted by the increase in computational power and developments in molecular biology,
drastic progress has been made in the field of protein design. Today, proteins are
engineered for increased stability and solubility, and for new or altered functionalities.
Computational protein design methods use force fields to select the optimal
sequence of amino acids for a target fold. They employ an energy potential, statistically
significant conformations of amino acids called rotamers and a selection algorithm,
which screens through the combinatorial complexity of the sequence space to obtain the
lowest energy sequences. In ORBIT (Optimization of Rotamers By Iterative Techniques),
the protein design program developed in our lab, the energy function is comprised of 5
terms: van der Waals, hydrogen bonding, electrostatic, solvation and entropy. The energy
function is empirical, but based on fundamental physical principles. A simple explanation
of each of the terms will be given below.
Description of the energy function in ORBIT
The van der Waals interaction is calculated using a Lennard-Jones 12-6 potential
(Figure 2A). This term is critical because it ensures a well-packed protein structure,
essential for the stability of folded proteins. Design methods that optimize only this term
3are still able to produce stable and folded mutants, which points to the importance of the
van der Waals term (Desjarlais and Handel 1995; Dahiyat and Mayo 1996; 1997b; Lazar
et al. 1997).
Hydrogen bonds are part electrostatic and part covalent interactions that have
been shown to be important in the design of enzymatic activities, binding sites and full
sequence designs (Dahiyat and Mayo 1997a; Looger et al. 2003). An angle-dependent,
12-10 hydrogen-bond potential is used in ORBIT (Figure 2B).
Electrostatics, like hydrogen bonds, is thought to be more important in the
specificity and functionality of proteins rather than their stability (Tanford et al. 1962).
Coulomb’s law is used to describe the electrostatic interactions in ORBIT (Figure 2C).
Our selection algorithm requires interactions to be described in a pairwise decomposable
manner, and Coulomb’s law satisfies this requirement. The Coulombic term is scaled
down through a distance dependent dielectric constant. This reflects the small
contribution of electrostatic interactions to protein stability.
When designing for binding and catalysis, electrostatic interactions in the active
site become important. For this purpose, a more accurate electrostatic function based on
physical properties is needed. Several different methods for continuum electrostatics
were recently modified to fit the need of protein design protocols. These include the
Poisson-Boltzman equation (Marshall et al. 2005), the Tanford-Kirkwood model
(Havranek and Harbury 1999), and the Generalized Born model (Pokala and Handel
2004).
The solvation term represents the interaction of the protein with water. The
protein’s aqueous environment influences its stability in two ways: (1) it causes the
4hydrophobic effect that provides the major driving force for protein folding (Kauzmann
1959); and (2) the solvent screens the electrostatic interactions. ORBIT utilizes a surface
area based solvation method (Figure 2D) (Street and Mayo 1998). This method penalizes
polar surface area burial and nonpolar surface area exposure, and benefits nonpolar
surface area burial. Recently, the Lazaridis and Karplus excluded volume model (LK
model) (Lazaridis and Karplus 1999) was successfully incorporated into ORBIT. Unlike
the surface area based solvation method, which is computationally expensive, the LK
model assumes that the solvation free energy can be decomposed into a sum of group
contributions that makes it computationally efficient. Ideally, an electrostatic term should
be able to describe all electrostatic interactions including hydrogen bonds and solvation.
Unfortunately, the implementation of such a description in protein design is intractable at
the moment, due to limitations in the selection algorithms and the available
computational power.
When a protein folds into its native structure from its unfolded state, it loses
conformational entropy. The native structure of the protein is the structure where the
enthalpic contributions from the native interactions outweigh the entropic loss of folding
to the maximum extent. Several different methods have been used in protein design to
describe this effect. Side chain entropy, calculated by considering all movable side chain
torsional angles at each residue, has been incorporated successfully (Hellinga and
Richards 1994). Backbone and side chain entropy values derived from the distribution of
rotamers in crystal structures have also been used (Filikov et al. 2002). The mean field
selection algorithm in which multiple rotamers are considered at each position
simultaneously provides an indirect way of incorporating side chain entropy into the
5design protocol (Koehl and Delarue 1994). Although these results show an improvement
in accuracy through the inclusion of a side chain entropy term, other studies have found
no improvement (Dahiyat and Mayo 1996; Kortemme and Baker 2002; Hu and Kuhlman
2006). Certain assumptions made in the entropy calculations might be responsible for
these contradictory results. In some methods, the conformational freedom is assumed to
be completely restricted in the folded state, while in other methods the unfolded state is
assumed to be completely unfolded and has no structure.
Even though an explicit entropy term is not included in ORBIT, there are negative
design terms that reflect some portions of the entropy term. For instance, the nonpolar
exposure penalty represents the hydrophobic effect that results from changes in the
entropy of the protein and water molecules during folding. An effect commonly seen in
proteins designed in the absence of an entropy term is the increase in the number of
methionines introduced into the core and the number of long positively-charged residues
on the surface. Our lab has made successful attempts to overcome these unnatural effects.
For the methionines, a penalty of 8kcal/mol was applied for any methionines that were
considered in the design. To reduce the amount of large positively charged residues on
the surface, we employed a baseline strategy in which the distribution of residues placed
on the protein surface was biased to be similar to the distribution obtained from a
statistical survey of the PDB database.
Proline is another residue that has been omitted in our designs due to the lack of
an entropic term. Proline residue is the only amino acid where the side chain is covalently
linked to the backbone, restricting its mobility. Thus, the backbone conformational
entropy loss upon folding is much less for prolines than all the other amino acids, thereby
6providing a stabilizing effect. In chapter 2, the effect of proline on protein stability is
analyzed by mutational studies on protein G. It is shown that prolines can both stabilize
and destabilize the protein depending on their local environment. This reconfirms the
general understanding that mutations to proline are stabilizing because of entropic
factors, although this behavior can be masked and even reversed by destabilizing
enthalpic changes. In the study, ORBIT was shown to predict the stability of the proline
mutants considerably well, likely due to the dominance of enthalpic contributions over
entropic contributions. Including a backbone entropy term with a proper weighing factor,
however, did increase the correlation between the experimental and the calculated
energies.
Applications of computational protein design
Computational protein design has two major applications: it is a convenient test
for our understanding of the physical properties of proteins; another is the more obvious
application of designing novel proteins for various purposes. Since it would be
impossible to list all of the applications of computational protein design here, I will
discuss three applications related to the projects in this thesis.
One application is the use of computational protein design to engineer peptides
that bind to proteins. Peptides have a high potential to be used as therapeutics because of
their small size, and a high affinity peptide for any receptor can be used as a competitor
in small molecule drug screening. Protein design algorithms have been utilized to design
high affinity peptides, and although their increase in affinity was modest, it was shown
that backbone flexibility gave better results than fixed backbone (Wollacott and
7Desjarlais 2001; Sood and Baker 2006). In chapter 3, we used ORBIT, which utilizes a
fixed backbone, to design a high affinity peptide for TRAF6 protein. All of our designed
peptides had affinities similar to the CD40 peptide. Surprisingly, the best peptide
designed had about a two-fold increase in its affinity, similar to the increase in affinity of
the peptides designed with flexible backbones. Thus, from our results it is not clear
whether the backbone flexibility is necessary for high affinity peptide design, although in
protein-peptide docking studies, the flexibility of both peptide and protein was necessary
to achieve good correlation between calculated binding energies and experimental
affinities (Liu et al. 2004).
Another protein design application that has recently gained much attention is the
design of protein biosensors. Proteins, because of their specificity in molecular
recognition of ligands, have a high potential to be developed into reagentless detectors for
a variety of molecules. The only deterrence is detecting the binding event, which can be
resolved by attaching fluorescent probes onto the protein at positions where
conformational change occurs with ligand binding. Cass and co-workers engineered the
maltose binding protein (MBP) for reagentless optical sensing of maltose by attaching
different thio-reactive fluorophores to it. They suggested that other periplasmic binding
proteins (PBPs) could be engineered as biosensors using a similar approach (Gilardi et al.
1994). Hellinga and coworkers took this suggestion and, using protein design methods,
designed a variety of PBPs into biosensors with novel specificity such as to Zn(II), TNT,
L-lactate, serotonin, PMPA and dihydroxyacetone phosphate (Dwyer and Hellinga 2004).
In chapter 4, the lipid transfer protein (LTP) from maize is developed into a scaffold for
the design of biosensors for hydrophobic ligands. The binding pocket of PBPs are small
8and hydrophilic, to accommodate their small and hydrophilic natural ligands. Although
PBPs were designed to recognize small non-native hydrophilic ligands, it would be an
extremely difficult task to design the PBP binding site to accept large hydrophobic
ligands and still retain their native fold. To expand the chemical scope of target ligands, a
protein that naturally binds to large hydrophobic molecules, the maize LTP, was selected
as a scaffold for biosensor design. To achieve this goal, the four disulfide bonds which
exist in all LTPs were designed out individually and the fluorophore attached LTP
variant, which shows the largest fluorescence intensity change after ligand binding, was
selected as a putative biosensor scaffold. With this scaffold, it will be possible to design
biosensors for hydrophobic ligands of interest.
Engineered proteins and peptides have high potential for use as therapeutics for a
variety of disease. This is because the design of protein therapeutics integrates the
traditional goals of protein design that include stability, solubility and binding specificity,
with biological and clinical parameters that include half-life, immunogenicity, toxicity
and degradation susceptibility (Lazar et al. 2003). Antibodies are epitope-specific, which
enable them to easily be used as therapeutics. By binding to specific antigens, antibodies
can block interactions; tag target molecules; lock proteins into specific conformation, and
even act as catalysts (Stocks 2004). Recently, the Fc region of an anti-tumor antibody
was designed using ORBIT for affinity and specificity for Fcγ receptors, increasing
cytotoxicity (Lazar et al. 2006). In chapter 5, a project is outlined where an intrabody that
binds to huntingtin protein is solubilized and stabilized by using ORBIT. This antibody
variant has the potential to be used as a therapeutic for the treatment of Huntington’s
disease.
9In Appendix A, a project involving the structure prediction of G protein coupled
receptors (GPCRs) is described. As explained above, the protein folding problem is much
more complex than the protein design problem (Figure 1). Predicting the structure of a
protein from its sequence has fascinated scientists for many years. Currently, with
CASP7 coming up, there is more interest in this problem than ever before. Structure
prediction methods can be divided into two broad categories. One category uses first
principles to predict the fold. The other category uses methods based on the identification
and utilization of related sequences and structures, such as in homology modeling and
fold recognition. As can be seen in the analysis of CASP6, the former gives more
accurate results and seems to be improving at a faster rate than the latter (Kryshtafovych
et al. 2005). Nevertheless, novel folds cannot be predicted by comparative modeling, thus
predictions based on the physical and chemical principles are important. The structure of
endothelial differentiation gene receptor, a GPCR that binds to sphingolipids, was
predicted using an ab initio computational structure prediction method. This method was
previously validated by predicting the three-dimensional structures of bacteriorhodopsin
and bovine rhodopsin for which crystal structural data are available (Vaidehi et al. 2002).
Docking procedures were used to obtain relative affinities for positive and negative
ligands and these values were compared to experimental results to validate our structure.
Although the model is a crude representation of the actual structure, it can be used to
predict positions for mutation to improve ligand binding.
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Figure 1. Protein design and protein folding problems.
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Figure 2. Potential energy function terms for ORBIT. (A) R:  interatomic distance
between the two atoms; D0: geometric mean of the well-depth of the two atoms; R0:
geometric mean of the van der Waals radius of the two atoms; α: van der Waals radius
scaling factor (B) R:  donor to acceptor distance; D0: hydrogen bond well-depth (8
kcal/mol); R0: hydrogen bond equilibrium distance (2.8 Å); F: angle term, which depends
on the hybridization state of the donor and acceptor (C) q: charge on atom 1; q ′: charge
on atom 2; r: interaction distance; ε: dielectric constant (D) Anp,b*: nonpolar buried
surface area; Ap,b*: polar buried surface area; Anp,e: nonpolar exposed surface area; σnp:
nonpolar burial energy; σp: polar burial energy; κ: nonpolar exposure multiplication
factor; c: polar hydrogen burial energy; Nbph: number of buried polar hydrogens not
involved in hydrogen bonds.
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A. Lennard-Jones 12-6 potential for van der Waals interaction
B. Hydrogen bond 12-10 potential
C. Coulombic function for electrostatic interaction
D. Surface area based solvation term
17
Chapter 2
Generation and analysis of proline mutants in protein G
The text of this chapter is adapted from the publication
Choi EJ and Mayo SL. Protein Eng Des Sel 2006, in press.
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Abstract
The pyrrolidine ring of the amino acid proline reduces the conformational
freedom of the protein backbone in its unfolded form and thus, enhances protein stability.
The strategy of inserting proline into regions of the protein where it does not perturb the
structure has been utilized to stabilize many different proteins including enzymes.
However, most of these efforts have been based on trial and error, rather than rational
design. Here, we try to understand proline’s effect on protein stability by introducing
proline mutations into various regions of the B1 domain of Streptococcal protein G.
Using two different solvation models, we also applied the ORBIT computational protein
design program to determine the extent to which it could predict the stabilizing and
destabilizing effects of prolines. The use of a surface area dependent solvation model
resulted in a modest correlation between the experimental free energy of folding and
computed energies; on the other hand, the use of a Gaussian solvent exclusion model led
to significant positive correlation. By including a backbone conformational entropy term
to the computational energies, we increased the statistical significance of the correlation
between the experimental stabilities and both solvation models.
19
Introduction
Proline is the only naturally occurring amino acid in which the side chain is
bonded to the backbone nitrogen, forming a five-membered pyrrolidine ring. This
pyrrolidine ring restricts the rotation of the N-Cα bond, decreasing the backbone
conformational entropy of the unfolded form of the protein relative to other naturally
occurring amino acids. This allows proline substitution to increase the stability of a
protein by decreasing the entropic difference between the unfolded and the folded form,
thereby increasing the free energy difference (Nemethy et al. 1966; Matthews et al.
1987). Based on this concept, different residues in various proteins have been mutated to
prolines, resulting in increased stability (Matthews et al. 1987; Watanabe et al. 1994).
On the other hand, prolines are also notorious for destabilizing proteins. It is well
known that prolines, located internally in α-helices or β-sheets, break these secondary
structures, thus destabilizing the protein. Two main factors cause prolines to break
secondary structures. One is the absence of the hydrogen on the amide nitrogen, which
prohibits prolines from acting as a donor in a hydrogen bond. Another is the steric
constraints placed on the proline and the neighboring residues by the pyrrolidine ring,
hindering secondary structure formation. The phi and psi angles preferred by prolines are
far from the typical range of those for β-sheets and thus, distort the strand significantly.
In addition, steric restriction drives the residue preceding proline to prefer the β
conformation, thus limiting the occurrence of prolines in α-helices.
Because of the contradictory effects described above, stabilization of proteins by
proline incorporation has typically been achieved by trial and error. The general
understanding is that proline mutation is stabilizing because of entropic factors, but this
20
behavior can be masked and even reversed by destabilizing enthalpic changes. Thus,
protein stabilization by prolines has been achieved by placing prolines in relatively
solvent-exposed locations where they would not disturb the stabilizing interactions of the
protein, for example in loops and turns or the first turn of an α-helix (Watanabe and
Suzuki 1998). Here we examine the effects of proline mutations in protein G and attempt
to “predict” these effects using computational tools with the aim of reasonably
incorporating the consideration of proline in computational protein design efforts.
Materials and methods
Mutagenesis and protein purification
Mutants of the B1 domain of protein G (Gβ1) were constructed by inverse
polymerase chain reaction in plasmid pET11A, expressed using BL21 (DE3) cells and
purified as previously described (Malakauskas and Mayo 1998). Two forms of Gβ1, 56
and 57 residue species, result due to incomplete processing of the N-terminal methionine.
In this study, the 56-residue species of Gβ1 mutants and wild type were used. Molecular
weights were verified by mass spectrometry.
Circular dichroism analysis
Circular dichroism (CD) data were collected on an Aviv 62DS spectrometer
equipped with a thermoelectric unit. Thermal denaturation experiments were monitored
at 218 nm from 1°C to 99°C by 1°C increments with an equilibration time of 1.5 minutes
using 50 µM protein in 50 mM sodium phosphate at pH 5.5.  The midpoint of the thermal
unfolding transition (Tm) was determined from a two-state analysis of each denaturation
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curve (Minor and Kim 1994). Guanidinium chloride denaturations were performed at
25°C using 5 µM protein in 50 mM sodium phosphate at pH 5.5. Data were collected for
5 minutes and averaged. Free energies of folding (ΔGf) and error estimates were obtained
by fitting the denaturation data to a two-state transition model (Santoro and Bolen 1988)
using Kaleidagraph (Synergy Software). Chemical and thermal melting curves for protein
G and its variants are presented in Figure 6.
Computational analysis
The crystal structure of wild-type Gβ1 (PDB entry 1pga) was used as the starting
template for energy calculations. Explicit hydrogens were added using MolProbity
(Lovell et al. 2003) and the structure was energy minimized for fifty steps to remove any
steric clashes (Mayo et al. 1990). For each mutant, proline was substituted at the selected
position and the protein design program, ORBIT (Optimization of Rotamers By Iterative
Techniques) (Dahiyat et al. 1997; Dahiyat and Mayo 1997a; b; Street and Mayo 1998;
Pierce et al. 2000), was used to optimize the structure (selecting the optimal rotamer for
proline as well as for all the other residues in the protein) and to calculate energies.
Solvation energies were calculated using either the method of Street and Mayo (1998) or
Lazaridis and Karplus (1999).
Results and discussion
Proline mutants of Gβ1
Prolines tend to have a phi angle of approximately -63°, while the psi angle
clusters around two regions in the Ramachandran map, -35°  (α region) and 150° (β
22
region) (MacArthur and Thornton 1991). We selected ten Gβ1 residues with phi and psi
angles compatible with proline for mutation: Thr2, Gly9, Lys10, Val21, Ala23, Ala24,
Thr25, Val29, Asp36 and Ala48. In order to explore the effect of prolines in different
structural environments, these residues were selected from various regions of the protein
(Figure 3). Thr2 and Gly9 are located in a β-strand. Ala23, Ala24 and Thr25 are the first
three N-terminal residues on the α-helix, Val29 is in the middle of the helix, and Asp36
is the C-terminal residue of the helix. The remaining residues are located in the loops and
turns connecting the secondary structural elements. The phi and psi angles of the
preceding residue of Thr2, Gly9, Lys10, Val21 and Ala23 are in the β region of the
Ramachandran map. Residues preceding proline prefer the β region because their Cβ and
amide nitrogen sterically conflict with the Cδ of proline (Schimmel and Flory 1968;
Matthews et al. 1987; Hurley et al. 1992).
Stability studies and analysis
The stability of each of the mutants was determined by performing thermal and
chemical denaturation experiments (Table 1 and Figure 6). The far UV CD spectra before
and after thermal denaturation indicate that all mutants except for K10P, T25P and V29P
fold reversibly (data not shown). The post-transition region of the melting curves for
V21P and V21P/A23P extends beyond the experimental range of 99°C, which leads to
large estimated errors.
As expected from the fact that proline is a well-known secondary structure
breaker, most of the proline mutants were less stable than the wild-type protein. An
exception to this is V21P, which exhibited a ΔGf enhancement of 0.5 kcal/mol and a Tm
23
increase of 6°C compared to the wild-type protein. This value agrees well with the
expected energy of stabilization generated by the entropic difference between Val and
Pro in the unfolded state. According to the method of Nemethy et al. (1966) a Val to Pro
mutation should increase stability by 0.5 kcal/mol, while the method of Stites and Pranata
(1995) suggests an increase of 0.3 kcal/mol at 25°C. Comparisons between mesophilic
and thermophilic proteins and mutational studies indicate that proline residues located in
loops help increase the rigidity of the loop and thus, increase the stability of the protein
(Vieille and Zeikus 1996). Val21 is the first residue in a two-residue loop, which
connects one of the edge strands of the β-sheet and the N-terminus of the α-helix. It is
solvent-exposed and does not interact with other residues; thus, mutation to proline does
not disturb any energetically favorable interaction. Given these observations, it is not
surprising that the increase in stability for V21P is close to the expected value.
Two residues, Lys10 and Ala48, are located in the i+1 position of a β-turn. The
fact that proline is the most favored residue for the i+1 position of β-turns has been
rationalized by analysis of protein structures. These studies reveal that prolines have phi
angles that are favored in that position (Hutchinson and Thornton 1994). In addition,
mutational studies report an increase in thermostability with proline substitution in this
position (Watanabe and Suzuki 1998). In our case, these two proline mutants are slightly
destabilizing compared to the wild-type protein. This may be partly due to the loss of a
hydrogen bond between the amide nitrogen of Ala48 and the carboxylate of Asp46, and
for Lys10, the loss of electrostatic interactions with negatively charged residues in the
vicinity (Asp40, Glu56 and the C terminal carboxyl group).
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  Prolines occur in the first turn of α-helices with high frequency. It has been
suggested that proline residues are not destabilizing in this position because the amide
hydrogens in the first turn do not make backbone/backbone hydrogen bonds within the
helix (von Heijne 1991). Within the first turn, prolines exist predominantly at the N1
position because steric clashes will result if the preceding residue is in a helical
conformation (Yun et al. 1991; Cochran et al. 2001). In our experiments, proline
mutation at the N2 position (A24P) was more destabilizing than mutation at the N1
position (A23P), consistent with previous observations. However, both proline mutations
were slightly destabilizing. Contrary to some mutational studies, but consistent with our
results for A23P and A24P as well as for K10P and A48P, peptide helicity measurements
demonstrated that prolines do not stabilize N terminal residues of α-helices or the i+1
residue of β-turns. Instead, it was suggested that prolines occur frequently in certain
locations because they are tolerated rather than stabilizing (Cochran et al. 2001). Proline
substitution at Thr25, which is located in the N3 position, was highly destabilizing with
ΔΔGf of 2.8 kcal/mol and Tm decrease of 21°C compared to the wild-type protein. The
amide nitrogen of residues in the first turn of an α-helix frequently makes hydrogen
bonds to a nearby side chain such as the N-cap residue in order to satisfy its hydrogen
bond donor potential. This is particularly true for the amide nitrogen of an N3 residue
which has frequently been observed to form a hydrogen bond to the N-cap side chain
(Penel et al. 1999). In the wild-type Gβ1 structure, the backbone and side chain of Thr25
make extensive hydrogen bonds with the carboxylate group of the N-cap residue, Asp22.
This interaction stabilizes and caps the first turn of the helix (Gronenborn et al. 1991).
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Substituting proline at this position eliminates this stabilizing interaction, thus
destabilizing the protein.
It has been reported that the cost of introducing a proline into an α-helix is about
3.4 kcal/mol (Oneil and Degrado 1990; Yun et al. 1991). Consistent with this, our Val29
to proline mutation destabilized the protein by 3.5 kcal/mol and decreased the Tm by
23°C.
Proline substitution in the β-sheet at Thr2 and Gly9 destabilizes the protein by
distorting the secondary structure of the β-sheet. The far UV CD spectra of these two
mutants deviate significantly from the wild-type spectrum, suggesting a change in
secondary structure content (data not shown).
Introduction of increasing numbers of prolines, up to nine, additively increased
the stability of oligo–1,6-glucosidase (Watanabe et al. 1994). To explore whether the
stabilizing/destabilizing effects of our proline mutants were additive, we constructed a
double mutant, V21P/A23P. To a first approximation, the effect was additive, resulting in
a near zero effect on stability, as can be seen in Table 1.
Comparison of computational and experimental energies
The energy of each of the mutants and the wild-type protein was calculated by
substituting proline at the respective positions and optimizing all side chains with
ORBIT. We used two different methods of calculating solvation energy, a surface area
dependent solvation model from Street and Mayo (1998) and a Gaussian solvent
exclusion model from Lazaridis and Karplus (1999). The energies are reported in Table
1. Mutants T2P, G9P, V29P and D36P showed significant backbone movement in the
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mutated region after minimization of the optimized structure determined by ORBIT
and/or exhibited large deviations of their far UV CD spectra compared to the wild type.
Since ORBIT utilizes the static backbone of the wild-type crystal structure for its
calculations, the ORBIT energy of these mutants is not likely to reflect the energy of the
true structure. Thus, they were not considered in the correlation analysis between the
calculated ORBIT energy (Ecalc) and ΔGf obtained by experiment. However, we would
like to point out that ORBIT does predict the destabilizing effects of three (G9P, V29P,
D36P) out of the four mutants excluded. These mutants all have very high computed
energies, due to large van der Waals clashes between the side chain and the backbone.
We propose that this is the reason for these mutants’ destabilization and deviation of their
CD spectra.
Excluding the mutants mentioned above, the agreement between the ORBIT
energy difference between the mutant (P) and the wild type (WT) (ΔEcalc(P-WT)), and the
experimentally determined free energy difference (ΔΔGf(P-WT)) resulted in an R2 values
of 0.79 using the Street and Mayo (SM) solvation model (Figure 4A), and 0.94 using the
Lazaridis and Karplus (LK) solvation model (Figure 5A). Correlation between Tm and
ORBIT energy resulted in R2 values of 0.78 and 0.79, for the SM and LK models,
respectively (Figure 4B and Figure 5B). In order to estimate the prediction error of
ORBIT energies more accurately and to consider whether the correlation for the data set
is dominated by the result for T25P, we used the “leave-one-out” cross validation method
on the free energy data set. The cross validation estimate of prediction error was 14.5 for
the SM method, while the LK method gave a significantly lower value of 0.12. Thus, the
Lazaridis and Karplus excluded volume solvation model based ORBIT energies show
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greater correlation to experimental ΔGu and a lower estimate of prediction error compared
to the surface area dependent solvation model based energies, suggesting that the LK
model performs better in describing the proline mutants. Overall, despite some false
positives, ORBIT is reasonably predictive in ranking the stabilities of the various mutants
as indicated by Spearman’s rank correlation coefficients of 0.75 (P < 0.01) and 0.93 (P <
0.01) for the SM and LK free energy correlations, respectively (data not shown).
In our hands, prolines have typically not been included in the set of amino acids
that ORBIT considers in protein design calculations because the potential energy function
used in ORBIT does not include a conformational entropy term. We tested whether
including a backbone conformational entropy term to the computational energy increases
the rank correlation between the experimental stabilities and computational energies.
Using the backbone entropy scale from Stites and Pranata (1995), the weighting factor for
the entropy term was determined by optimizing for the rank correlation between the
experimental and computational results. For computational energies calculated with the
LK model, a weighting factor in the range of 2.9 to 12.9 gave a rank correlation of 0.96
(P < 0.01). For those calculated with the surface area based method, a weighting factor in
the range of 15.01 to 15.2 also gave a rank correlation of 0.96 (P < 0.01).
As described above, proline stabilizes a protein by decreasing the backbone
conformational entropy of the unfolded state. ORBIT predicts the stability of proline
mutations reasonably well without an entropic term.  This is likely due to the dominance
of enthalpic contributions over entropic contributions in protein stability modulation by
prolines, which overshadows the missing entropic term in the energy function.
Nevertheless, addition of an entropic term with an appropriate weighting factor increases
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the correlation between computational energy and experimental energy, especially for the
surface area based solvation method.
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 Table 1. Midpoint of thermal unfolding transition (Tm), free energy of folding (ΔGf)
at 25°C, and computed energy for Gβ1 variants (errors determined from non-linear
fits)
Name Tm(ºC)
∆Gf
(kcal/mol)
∆∆Gf
(kcal/mol)
Ecalc (SM)1
(kcal/mol)
Ecalc (LK)2
(kcal/mol)
wild type 89.6 ± 2.6 -5.9 ± 0.4 -90.1 -72.2
T2P 83.0 ± 1.2 -3.2 ± 0.3 2.7 -90.5 -72.9
G9P 72.6 ± 0.7 -3.5 ± 0.3 2.4 120.2 146.9
K10P 81.2 ± 1.1 -5.7 ± 0.4 0.2 -89.0 -71.9
V21P 95.8 ± 14.3 -6.4 ± 0.4 -0.5 -90.5 -73.2
A23P 88.2 ± 1.9 -5.6 ± 0.5 0.3 -93.5 -72.7
A24P 85.0 ± 0.8 -5.4 ± 0.3 0.5 -90.1 -71.2
T25P 68.7 ± 0.4 -3.1 ± 0.2 2.8 -77.5 -60.4
V29P 67.0 ± 0.5 -2.4 ± 0.2 3.5 1464.7 1487.1
D36P 68.6 ± 0.8 -2.8 ± 0.3 3.1 3310.3 3330.0
A48P 82.8 ± 0.7 -5.2 ± 0.3 0.7 -86.4 -70.8
V21P/A23P 96.5 ± 28.4 -5.8 ± 0.4 0.1 -93.9 -73.8
1ORBIT energy using Street and Mayo (1998) solvation model.
2ORBIT energy using Lazaridis and Karplus (1999) solvation model.
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Figure 3. Views of the 10 positions in Gβ1 mutated to proline. These structural figures
were generated using VMD (Humphrey et al. 1996).
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Figure 4. Correlation between calculated energies, using the Street and Mayo (1998)
solvation model, and experimental results. (A) Comparison of experimental (∆∆Gf) and
calculated (Ecalc) stability change between mutant and the wild type. (B) Comparison of
Tm and calculated energy.
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Figure 5. Correlation between calculated energies, using the Lazaridis and Karplus
(1999) solvation model, and experimental results. (A) Comparison of experimental
(∆∆Gf) and calculated (Ecalc) stability change between mutant and the wild type. (B)
Comparison of Tm and calculated energy.
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Figure 6. CD data. (A) Thermal and  (B) guanidinium chloride denaturation curves for
the various proteins included in this study.
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Chapter 3
Analysis of computationally designed TRAF6 binding
peptides
45
Abstract
Members of the tumor necrosis factor receptor (TNFR) associated factor (TRAF)
family bind to a variety of cell surface receptors and are involved in adaptive and innate
immunity, stress response and tissue homeostasis. Starting with the TRAF6-CD40
peptide complex crystal structure, we used the ORBIT computational protein design
software to design peptides that would bind to TRAF6 with high affinity. A fluorescence
anisotropy binding assay was developed and used to measure binding affinities. All
designed peptides had binding affinities similar to the CD40 peptide, with the best
showing about a two-fold increase.
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Introduction
Tumor necrosis factor receptor (TNFR) associated factors (TRAFs) bind to a
variety of cell surface receptors, acting as adaptors in the activation of diverse down
stream molecules. They are involved in a wide range of biological functions, including
adaptive and innate immunity, stress response and tissue homeostasis (Chung et al.
2002). To date, seven members of the TRAF family have been identified in mammals:
TRAF1-7. All TRAF family proteins, excluding TRAF7, contain a TRAF domain at the
carboxy terminus, which is further divided into an amino terminal TRAF-N domain and a
highly conserved carboxy terminal TRAF-C domain. The TRAF-N domain forms a
coiled coil and is involved in oligomerization, while the TRAF-C domain forms an
antiparallel β sandwich and interacts with upstream receptors (Figure 7) (Park et al. 1999;
Ye et al. 2002a).
TRAF6 mediates signal transduction for members of both the TNFR superfamily
and the interleukin-1 receptor (IL-1R)/Toll-like receptor (TLR) superfamily. Among the
TNFR superfamily members, the interaction of TRAF6 with CD40 and RANK has been
studied extensively. TRAF6 plays an important role in CD40-induced activation of
antigen presenting cells and interacts with RANK and thus, affects dendritic cell survival
and osteoclast differentiation. TRAF6 differs from the other members of the TRAF
family in many ways. It has a unique recognition motif (Pro-X-Glu-X-X-aromatic/acidic
residue) and a different mode of ligand binding. Comparison of TRAF6 and TRAF2
crystal structures reveals completely different ligand binding sites. The direction of the
bound peptides differs by 40°  and TRAF6 ligands assume an extended beta
conformation, while TRAF2 ligands are helical (Ye et al. 2002a). TRAF6 is also very
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unique in that it activates transcription factors through different downstream components
and is the only TRAF known to activate the Src tyrosine kinase family. TRAF6 plays a
critical role in (1) adaptive immunity by interacting with CD40 and RANK; (2) bone
resorption by interacting with RANK; and (3) innate immunity by interacting with
members of the IL-1R/TLR superfamily. TRAF6 has also been implicated in the
development of epidermal appendices and central nervous system development (Wu and
Arron 2003).
Recently, Wu and co-workers determined the crystal structures of the TRAF-C
domain of TRAF6 alone and in complex with receptor peptide ligands. The authors
showed that the peptide ligands block TRAF6 mediated signal transduction in RAW264.7
cells and primary mouse derived monocytes. These cells differentiate into multinucleated,
tartrate resistant acid phosphatase (TRAP)-positive osteoclasts when stimulated with
TRANCE, the ligand for RANK. When co-treated with TRAF6 binding peptide ligands,
they observed a dose-dependent decrease of TRAP-positive osteoclasts (Ye et al. 2002a).
These results suggest that high affinity peptide ligands of TRAF6 may prove useful in the
treatment of osteoporosis.
With this in mind, we used the ORBIT (Optimization of Rotamers By Iterative
Techniques) protein design software to design several peptide ligands for TRAF6. The
binding affinities of the peptides were determined using anisotropy from the fluorophores
attached to the peptides. This method was used instead of isothermal titration calorimetry
(ITC), which has been employed by others, because the aggregation-prone characteristics
of the protein gave inconsistent results in our ITC experiments. The sensitivity of
fluorescence anisotropy allowed us to use nanomolar concentrations of proteins while
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ITC experiment required 10-fold excess. All our designed peptides exhibited binding
affinities similar to the CD40 peptide, suggesting that the CD40 peptide is highly
optimized for the wide binding groove of the TRAF6 protein. Our best design showed a
two-fold improvement in TRAF6 binding affinity compared to the CD40 peptide. Since
TRAF6 depends on avidity based affinity enhancement (Ye and Wu 2000), we predict
that in the context of the full trimer protein receptor, our best design will show over an
eight-fold enhancement in TRAF6 binding affinity compared to CD40.
Materials and methods
Protein purification and peptide synthesis
TRAF6 constructs (residues 333-508) containing part of the TRAF-N domain and
all of the TRAF-C domain were obtained from Dr. Hao Wu (Cornell Medical College)
and was previously described (Ye et al. 2002b). The constructs were expressed in BL21
(DE3) cells and induced overnight at 20°C. The recombinant proteins were purified by
Ni2+ affinity chromatography and gel filtration using a Superdex 200 column (GE
Healthcare). All peptides were chemically synthesized at the Biopolymer Synthesis
Center, California Institute of Technology. All peptides used in the fluorescence assay
were synthesized with fluorescein attached to the amino terminus and an amide group
attached to the carboxy terminus. The peptides used in ITC experiments were acetylated
at the amino terminus and amidated at the carboxy terminus to mimic the intact protein.
The molecular mass of each peptide was verified by matrix assisted laser desorption
ionization time of flight (MALDI-TOF) mass spectrometry. The CD40 peptide used in
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this study is a variant from wild-type, with an Asn to Asp mutation at the P2 position to
enhance affinity to TRAF6.
Computational methods
The 1.8 Å resolution crystal structure of TRAF6 in complex with the nine-residue
human CD40 peptide (PDB ID: 1LB6) was used as the initial structure for ORBIT.
Explicit hydrogens were added using MolProbity (Lovell et al. 2003) and the structures
were minimized for 50 steps to remove any steric clashes. For all designs, ORBIT was
used to calculate the energies and predict the global minimum energy conformation
(GMEC) sequence (Dahiyat et al. 1997; Dahiyat and Mayo 1997a; b; Street and Mayo
1998; Pierce et al. 2000). We used a large backbone-dependent rotamer library, which
was expanded about the χ1 and χ2 dihedral angles by one standard deviation. On the
nine-residue CD40 peptide, three consensus residues (P-X-E-X-X-F) and the first residue,
which did not make direct contact with TRAF6, were excluded from the design; the other
five residues were allowed to change identity. On the TRAF6 protein, residues within 12
Å of the peptide were allowed to change conformation, and the rest were held fixed.
Interaction energies were calculated by using a Monte Carlo search algorithm. 1000 best
(lowest energy) sequences were obtained by using the GMEC as the starting structure.
The apo-TRAF6 and the peptide ligand were separated in each of these 1000 protein
peptide complexes, and their individual energies were calculated and subtracted from the
energy of the complex to obtain the interaction energy. The sequences were resorted by
interaction energy and the top ranking sequences were inspected visually. ORBIT
optimizes for all interactions in the modeled structure, whether they are intramolecular or
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intermolecular. To circumvent this problem, we used a modified energy function that
biases toward intermolecular interactions (Shifman and Mayo 2003).
Isothermal titration calorimetry (ITC) and fluorescence anisotropy measurement
ITC data were obtained using a micro calorimetry system from MicroCal
(Amherst, Ma). All titration experiments were done at 20°C. 5 mM peptide ligand was
injected into 1.5 ml of 0.03 ~ 1.1 mM TRAF6 in 3 ~ 5 µl volumes. The titration data
were analyzed with the ORIGIN software (MicroCal). The constant heat at the end of the
experiment was assumed to be the control background heat and was subtracted out from
the raw data before fitting. Nonconstraint fitting was performed for all the samples to
extract the binding affinity (Kd).
Fluorescence anisotropy data were obtained using a fluorometer from Photon
Technology International (Lawrenceville, NJ). Experiments were done at room
temperature or at 4°C.  Serial dilutions of TRAF6 were prepared with 12.5 nM of peptide
at final volume of 1 ml. All samples were incubated overnight at 4°C and measurements
were taken immediately thereafter. Anisotropy measurements were taken for 1 minute
and averaged. The average anisotropy and the concentration of TRAF6 were plotted and
fit to a binding equation by nonlinear least squares analysis (Lundblad et al. 1996) using
Kaleidagraph (Synergy Software).
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Results and discussion
Parameterization of ORBIT for the design of high affinity peptides
ORBIT was developed and optimized for stabilization of single isolated proteins
with emphasis on hydrophobic packing. We therefore predicted that the default
parameters used for protein stabilization would not be optimal for increasing the affinity
between a peptide and a protein, especially for TRAF6 and CD40 peptide, where there is
little hydrophobic contact. To determine the best combination of ORBIT parameters for
this system, we analyzed the results of an experimental colorimetric binding assay in
which all the binding site residues were singly substituted to all 20 amino acids (Pullen et
al. 1999). Peptide sequences from the assay were divided into two categories: those that
bind to TRAF6 (binder), and those that do not (nonbinder). We tried different force field
parameter values to calculate the energies of all the peptides used in the experimental
assay by ORBIT and looked at how well the energies correlated with the experimental
results. We varied the distance dependent dielectric constant (4r or 40r), and used surface
area based solvation with either penalties for polar hydrogen burial or polar surface area
burial. We calculated two energies: total energy and interaction energy, defined as the
sum of all enthalpic interaction energies between the protein and the peptide. The
goodness of fit between the experimental data and the computed energies was determined
using two scores: T test between the mean energies of the binders and the nonbinders,
and the number of false positives. False positives were defined as nonbinders with total
energy or interaction energy better than the median of the binders’ energies. The results
were first sorted by the T score, then the number of false positives were taken into
consideration (Table 2). Overall, using total energies gave better correlations than using
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interaction energies, and in contrast to our prediction, the default parameter set used in
designing isolated proteins ranked very well. We selected four peptides to test
experimentally: three were obtained from calculations with parameters which had high-
ranking T scores and were selected based on total energies (D1 to D3), and one was
predicted using interaction energies (D4) (Table 2).
Binding affinity measurements
Previously, affinities of various peptides to TRAF6 were determined by ITC (Ye
et al. 2002a). Unfortunately, in our hands, TRAF6 had limited solubility and aggregated
during the ITC run, giving us inconsistent binding results that were, on average, an order
of magnitude better than the published values. We therefore developed a fluorescence
anisotropy assay to determine the binding affinity of the designed peptides (Figure 8 and
Table 3). We synthesized four of the peptides ORBIT predicted using the parameters
described above (D1 to D4, Table 3) and measured their binding affinities. Designed
peptides D3 and D4 were overly hydrophobic, so additional PDD sequence was added to
their C terminus to improve solubility. All affinities reported in Table 3 are relative to the
CD40 peptide of the same length as the peptide tested (9-residue or 12-residue).
Surprisingly, the Kd values we obtained by fluorescence anisotropy were similar to the Kd
values obtained with ITC, and were an order of magnitude better than the Kd value
previously reported using ITC (Ye et al. 2002a) (Table 4). Nevertheless, we are confident
of the relative affinities from our anisotropy measurements because the standard
deviations from multiple experiments are very small (Table 4). Our anisotropy assay was
tested for nonspecific binding with two negative control mutant CD40 peptides. The two
53
negative control peptides used were a mouse CD40 peptide with the Pro at P-3 position
mutated to Gln (mCD40-P/Q) and human CD40 peptide with the Pro at P-3 position
mutated to Gly and Glu at P0 position mutated to Ala (CD40-P/G,E/A) (Table 3).
Previously, mCD40-P/Q was shown to have about half the activity of wild-type mouse
CD40 peptide in an NF-κB reporter activity assay, and CD40-P/G,E/A was shown in
vitro to have no affinity for TRAF6 (Pullen et al. 1999; Ye et al. 2002a). In our
anisotropy assay, both show little or no binding to TRAF6 (Figure 8).
Other design trials
In the initial designs, our best peptide (D1) exhibited about a two-fold affinity
enhancement compared to the CD40 peptide sequence. This improvement encouraged us
to try to design a better binder using the knowledge gained from the first four peptides.
We decided to use ORBIT’s bias function , described in the methods section, to favor the
intermolecular interactions between the peptide side chains and the TRAF6 side chains.
Using the parameters for D1, we applied a 2-fold bias and a 4-fold bias to the
intermolecular optimization, which resulted in the two sequences, D5 and D6 (Table 3).
Both are one mutation away from D1, at the P1 position: instead of an Ile at P1, D5 has a
Leu, and D6 has a Trp. Interestingly, the exact same sequences are obtained when the
parameters for D2 are biased 2-fold and 4-fold. We expected D5 to have less affinity for
TRAF6 because Ile has higher beta strand propensity than Leu. The ligand peptide binds
to TRAF6 in an extended beta strand conformation and a Leu instead of Ile should
destabilize the peptide in the beta strand conformation. As predicted, D5 has significantly
lower affinity than CD40 peptide. The experimental data of Pullen and co-workers
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indicated that D6, however, might bind tighter. This data was used above in determining
the ORBIT parameters, in which all 20 amino acids were substituted in all positions of
the peptide and binding was observed using membrane binding assays. In their assay,
substituting Trp for Ile resulted in 4-fold better binding to TRAF6. In our anisotropy
assay, D6 affinity was similar to the wild-type sequence and less than D1. This might be
explained by the fact that Pullen and co-workers used a crude colorimetric plate assay
while we used purified proteins in a solution state assay. Also, their Trp mutation is in the
context of the naturally occurring wild-type sequence, while our designed peptide has
two other residues different from the naturally occurring CD40 peptide.
Comparing the D1, D2, D5 and D6 sequences indicates that among the residues
tested at P1, Ile is the most stable. Met, on the other hand, was thought to be destabilizing
because of the large entropic loss upon binding. We therefore synthesized and tested
another peptide (D7) with the same sequence as D3, but with Ile instead of Met at P1. Ile
turned out to be less optimal than Met in the context of D3, resulting in decreased binding
affinity.
Another strategy we tried was to design one of the conserved sequences. When
the peptide residues are classified as core, boundary or surface (Dahiyat and Mayo
1997a), only the Pro located in the P-2 position is classified as core. This suggested that
P–2 is the anchoring position in the TRAF6-peptide interaction, and that it makes a large
contribution to the binding affinity. It has been shown that hydrophobic interactions are
important in affinity while polar interactions are important for specificity (Clackson and
Wells 1995). Taking this into consideration, the P-2 residue, which is the only completely
buried residue at the interface, was thought to be important in determining the binding
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affinity of the peptide. To determine whether a larger hydrophobic side chain at P-2 would
be allowed, we ran three side chain replacement calculations substituting the Pro to Phe,
Tyr and Trp. There were no significant steric clashes with all three substitutions when the
VDW scale factor for D1 design (0.9) was used. Trp and Phe had high nonpolar
exposure, while the hydroxyl group of Tyr made a favorable hydrogen bond with Asp451
of TRAF6. Thus, we decided to test out a peptide with the same sequence as D1 except
for a Pro to Tyr substitution at P-2 (D8). Unfortunately, the Pro to Tyr mutation decreased
the binding affinity to 9% of D1. This implies that Tyr might be sterically clashing with
TRAF6, which did not show in our side chain replacement calculation because of the
small VDW scale factor used.
Affinity versus avidity
It has been pointed out that the low affinity nature of TRAF-receptor ligand
binding ensures that TRAFs bind to their receptors only when the receptors are trimerized
and active (Ye and Wu 2000). The structural characteristics of the binding site, which
forms a wide and shallow groove, implies a relatively flat binding energy landscape that
allows many different sequences to attach, however with low affinity. In addition, the
peptide ligand assumes an extended beta conformation when fitting into this binding site,
allowing only half of the residues of the peptide to face the protein and be involved in
direct contact (Figure 7) The other side chains are facing away from the protein and thus,
are highly exposed to the solvent, which may decrease their hydrogen bonding and
electrostatic interaction contribution to the binding energy. The fact that the majority of
the hydrogen bonding interactions between TRAF6 and the peptide ligand in the crystal
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structure are between backbones and that only one interface residue is fully buried
implies that the binding affinity between the peptide and protein will be nontrivial to
optimize. We have tried to overcome this difficulty by using a biased energy function to
optimize specifically for interactions between the side chains of the peptide and TRAF6,
but this did not result in a high affinity peptide (D5 and D6). It could be that nature has
designed the binding interface of TRAF6 and its receptor to maintain low affinity so that
affinity can be achieved through avidity. The fact that the affinities of naturally occurring
TRAF6 binding domains are all in the micromolar range (Ye et al. 2002a), even though
the sequence diversity is very high in the nonconsensus positions, also supports this
hypothesis.
The dynamic nature of proteins is not represented in our design protocol, which
employs a fixed backbone. Flexible backbones have been successfully used to design
single proteins (Harbury et al. 1998; Larson et al. 2002; Kraemer-Pecore et al. 2003;
Kuhlman et al. 2003). Recently, several groups have also designed protein-binding
peptides using this method (Wollacott and Desjarlais 2001; Sood and Baker 2006). In
these studies, a flexible backbone was necessary to obtain the sequence diversity of
experimentally verified ligands. This indicates that a flexible backbone is desirable for
successful design and specificity prediction. It would be interesting to see whether a
flexible backbone will improve the design effort for the TRAF6 and CD40 peptide
system. On the other hand, some results imply that a flexible backbone is not necessary,
and that allowing side chain flexibility or decreasing the van der Waals radii scale of the
atoms to reduce the effects of using discrete rotamers and a fixed backbone is enough to
obtain good results (Su and Mayo 1997; Desjarlais and Handel 1999). If this is the case,
57
our design, which used a large rotamer library with expansion about both χ1 and χ2, and
used 0.9 van der Waals scale factor, should give an optimal sequence, even though
backbone flexibility was not included. Even with a flexible backbone, the affinity
increase for the best designed peptide for the dystrophin protein and Mdm2 were very
modest (2.3 fold and 1.3 fold, respectively), comparable to the result we obtained for
TRAF6 using a fixed backbone (Sood and Baker 2006). The authors attributed this to the
fact that the binding groove is shallow and flat, which is also the case with our protein
system. This suggests that a flexible backbone might not benefit designs for our protein
system.
We used the ORBIT protein design software to design eight peptides to bind to
TRAF6. The relative affinities of our peptides compared to the CD40 peptide ranged
from 16% to172%. The modest affinity increase of the best design and the overall similar
affinities of all the peptides might be due to the wide, shallow binding site on TRAF6. A
high affinity peptide binder might be disallowed because the entropic cost of rigidifying a
nine-residue peptide might be much higher than the optimal enthalpic benefit that can be
achieved with an extended beta conformation peptide at such a wide and shallow binding
site.
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Table 2. Parameters used to fit experimental binding assay data with computational
energies, T test scores and the number of false positives for all the parameters are shown.
The parameters in red were used to design peptides used in fluorescence anisotropy
assays. The name of the designed peptides are written as a superscript. The underlined
parameter set is the default parameter set for ORBIT, which is used to design isolated
proteins. polar SA: polar surface area penalty; polar H: polar hydrogen penalty; Total E:
total energy; Intxn E: interaction energy.
Parameters
Dielectric
constant
Solvation
penalty
Energy
score T test
# false
positives
40r polar SA Total ED3 0.0012 23
4r polar SA Total E 0.0024 14
4r polar H Total ED2 0.0054 30
40r polar H Total ED1 0.0073 22
4r polar SA Intxn E 0.0175 25
40r polar SA Intxn E 0.0228 29
40r polar H Intxn ED4 0.0394 23
4r polar H Intxn E 0.1905 47
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Table 3. Sequences and relative affinities of designed peptides.
P-5 P-4 P-3 P-2 P-1 P0 P1 P2 P3 P4 P5 P6
Relative
affinity*
CD40 peptide K Q E P Q E I D F P D D 1.00
D1 - R - - E - - - - 1.72
D2 - R - - E - H - - 0.50
D3 - I H - E - M - - - - - 0.43
D4 - - Q - E - - - - - - - 0.83
D5 - R - - E - L - - 0.36
D6 - R - - E - W - - 0.89
D7 - I H - E - - - - - - - 0.33
D8 - R - Y E - - - - - - - 0.16
mCD40-P/Q R - D Q - - M E D ~0
CD40-P/G,E/A - - - G - A - N - - - - ~0
Residue position nomenclature derived from Ye et al. (2002a).
* Relative affinity is defined as the Kd of the peptide divided by the Kd of the CD40
peptide that has the same length, either 9 or 12 residues, as the peptide. All affinities were
obtained by fluorescence anisotropy assay.
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Table 4. Comparison of affinities obtained by fluorescence anisotropy assay and ITC.
Previously measured value from Ye et al. (2002a) is also shown for CD40 peptide.
Kd from
fluorescence
anisotropy (µM)
Kd from ITC (µM)
Kd from ITC (Ye
et al. 2002a) (µM)
9 residue CD40 peptide 7.4 ± 1.1 8.8 ± 1.0 84
9 residue D1 4.3 ± 0.6 7.8 ±3.2
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Figure 7. Ribbon and molecular surface representation of TRAF-C domain of TRAF6
bound to CD40 peptide (PDB ID: 1LB6). These structural figures were generated using
VMD (Humphrey et al. 1996).
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Figure 8. Anisotropy data of all the peptides. (A) Data for all nine residue peptides. (B)
Data for peptides with additional three residues, PDD, attached to the carboxy terminus
to increase the solubility of the peptide. CD40_N: wild-type CD40 peptide; CD40_D:
wild-type CD40 peptide with Asn to Asp mutation at P2 position.
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Chapter 4
Computational design and biochemical characterization
of non-specific lipid transfer protein variants for
biosensor applications
The text of this chapter is adapted from the manuscript to be submitted by Choi EJ, Mao
J and Mayo SL (in preparation).
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Abstract
Lipid transfer proteins (LTPs) are a family of proteins that bind and transfer
lipids. Utilizing a maize LTP, we have successfully engineered a fluorescent reagentless
biosensor for the natural ligand of LTPs; this was achieved by using computational
protein design to remove disulfide bridges and attaching a thio-reactive fluorophore. Our
LTP variants show affinity to palmitate on the order of the wild-type LTP. These
molecules can be used to design biosensors with specificities for various hydrophobic
ligands. They can also be used as drug carriers.
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Introduction
Biosensors are biological molecules that recognize specific ligands and relay the
message to a physical signal, which can be easily detected and measured. Ideally, a
biosensor is reagentless and does not change composition as a consequence of the
measurement. The specific interaction of a biosensor with its ligand and its reagentless
characteristic allow biosensors to be the basis for a wide range of assay methods.
Recently, bacterial periplasmic binding proteins (PBPs) with different ligand specificities
were tagged with a fluorophore to produce biosensors for their natural ligands, which
include sugars, amino acids, dipeptides and ions (de Lorimier et al. 2002). Furthermore,
using protein design techniques, these proteins were engineered into biosensors with
specificity for novel ligands such as Zn(II), TNT, L-lactate, serotonin, PMPA and
dihydroxyacetone phosphate (Dwyer and Hellinga 2004).
The natural ligands of PBPs are hydrophilic and relatively small. The binding site
residues are also hydrophilic, thus making it difficult to design in large hydrophobic
ligands. Our aim is to expand the chemical scope of target ligands by developing a
protein platform capable of specifically binding large and/or hydrophobic ligands. For
this purpose, we selected nonspecific lipid transfer protein (LTP) from maize (mLTP).
Plant LTPs are a family of proteins known for their ability to bind and transfer lipids.
Their biological function is still unclear, but they may be involved in the formation of the
cuticle layer, in somatic embryogenesis and in plant responses to pathogenic stress. The
two subfamilies of LTPs (LTP1 and LTP2) share eight conserved cysteines that form four
disulfide bridges and have nonpolar binding pockets (Capocchi et al. 2005). The larger
LTP1 binds various phospholipids, fatty acids, and glycolipids, while the smaller but
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more flexible LTP2 can bind to bulkier sterol molecules as well (Samuel et al. 2002;
Cheng et al. 2004).
In this paper, we used mLTP to design a biosensor for its natural lipid ligands.
mLTP is a 93-residue basic protein comprised of four α-helices (helix 1-4). It is of the
LTP1 subfamily and has a tunnel-like hydrophobic cavity that has one wide and one
narrow opening on either end. The wide opening is predicted to be the main entrance or
exit site for the ligands (Shin et al. 1995; Gomar et al. 1996; Han et al. 2001). The apo-
mLTP does not have a tightly packed hydrophobic core because of this hydrophobic
cavity, and it is thought that the disulfide bonds are important in maintaining the tertiary
structure of the LTPs in the absence of the ligand. Our strategy is to design out the
disulfide bonds using ORBIT (Optimization of Rotamers By Iterative Techniques) to
allow flexibility in the mLTP molecule. Acrylodan, a thiol-reactive fluorescent probe,
will be conjugated to one of the cysteines that are not designed out. We predict that when
the ligand is added to the flexible mLTP variant, it will bind to the protein, rigidifying it
and changing its conformation, causing a fluorescence change. The small size and the
availability of a high-resolution crystal structure of mLTP with its ligand bound makes it
a good candidate for computational protein design (Shin et al. 1995).
Recently, there has been an interest in using proteins as carriers for drugs due to
their high affinity and selectivity for their targets (De Wolf and Brett 2000). The proteins
would not only protect the unstable or harmful molecules from oxidation and
degradation, but they would also aid in solubilization and ensure a controlled release of
the agents. In a study to determine the suitability of LTPs as drug carriers, various
molecules having cosmetic or pharmacological interest were tested for binding to wheat
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LTP (wLTP). wLTP was found to bind to a variety of molecules with affinities low
enough to allow a slow release (Pato et al. 2001). Our acrylodan-conjugated mLTP
variants could be used in a reliable, sensitive, high throughput screening method for
binding drug compounds. Also, LTP variants designed to bind a specific ligand could be
used as drug carriers.
Materials and methods
Computational protein design
The crystal structure of mLTP with palmitate (PDB ID 1MZM) was briefly
energy minimized and its residues were classified as surface, boundary, or core based on
solvent accessibility (Dahiyat and Mayo 1997a). Each of the four disulfide bridges was
individually reduced by deletion of the S-S bond and addition of hydrogens. The
corresponding structures were used in designs for the respective disulfide bridge.  The
ORBIT protein design program uses an energy function based on the DREIDING force
field, which includes a Lennard-Jones 12-6 potential with all van der Waals radii scaled
by 0.9, hydrogen bonding and electrostatic terms and a solvation potential (Mayo et al.
1990; Dahiyat et al. 1997; Dahiyat and Mayo 1997b). Both solvent-accessible surface
area-based solvation (Street and Mayo 1998) and the implicit solvation model developed
by Lazaridis and Karplus (Lazaridis and Karplus 1999) were tried, but better results were
obtained with the Lazaridis-Karplus model, and it was used in all final designs. From the
fixed composition study on the Engrailed homeodomain protein, polar burial energy was
scaled by 0.6 and rotamer probability was scaled by 0.3 (Oscar Alvizo, unpublished
data).  Parameters from the Charmm19 force field were used. An algorithm based on the
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dead-end elimination theorem (DEE) was used to obtain the global minimum energy
amino acid sequence and conformation (GMEC) (Pierce et al. 2000). For each design,
non-proline, non-glycine residues within 4 Å of the two reduced cysteines were included
as the 1st shell of residues and their amino acid identities and conformations were
optimized. Residues within 4 Å of the 1st shell were considered the 2nd shell and they
were floated; that is, their conformations were allowed to change, but their amino acid
identities were held fixed.  Finally, the remaining residues were treated as fixed. Based
on the results of the initial design calculations, further restricted designs were carried out
where only designed positions making stabilizing interactions were included.
Designed protein expression and purification
The E. coli expression optimized gene encoding the mLTP amino acid sequence
was synthesized and ligated into the pET15b vector (Stratagene) by Blue Heron
Biotechnology (www.blueheronbio.com). The pET15b vector includes an N-terminal
His-tag.  Inverse PCR mutagenesis was used to construct five variants, C4H/C52A/N55E,
C4Q/C52A/N55S, C14A/C29S, C30A/C75A and C50A/C89E. The proteins were
expressed in BL21(DE3) Gold cells (Stratagene) at 37°C after induction with IPTG
(isopropyl-beta-D-thiogalactopyranoside). Cells were resuspended in lysis buffer (50 mM
sodium phosphate, 300 mM sodium chloride, 10 mM imidazole, pH 8.0) and lysed by
passing through the Emulsiflex at 15,000 psi, and the soluble fraction was isolated by
centrifugation at 20,000g for 30 minutes. The soluble fraction of the cell lysate was
loaded onto a Ni-NTA column and eluted with elution buffer (lysis buffer with 400 mM
imidazole). The elutions were further purified by gel filtration chromatography with
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phosphate buffer (50 mM sodium phosphate, 150 mM sodium chloride, pH 7.5).  The
molecular weight and the oxidation state of the purified proteins were verified by SDS-
Page and MALDI-TOF. Trypsin digest analysis showed that the N-terminal Met was
cleaved. The gel filtration profile for all variants looked similar to that of wild-type
mLTP, which we verified to be a monomer by analytical ultracentrifugation (data not
shown). Protein concentration was determined using the BCA assay (Pierce) with BSA as
the standard.
Circular dichroism
Circular dichroism (CD) data were obtained on an Aviv 62A DS
spectropolarimeter equipped with a thermoelectric cell-holder. Wavelength scans and
thermal denaturation data were obtained from samples containing 50 µM protein.  For
wavelength scans, data were collected every 1 nm from 190 to 250 nm with averaging
time of 5 seconds. For temperature denaturation, data were collected every 2°C from 1°C
to 99°C using an equilibration time of 120 seconds and an averaging time of 30 seconds.
Since the thermal denaturations were not reversible, we could not fit the data to a two-
state transition. The apparent melting temperatures (Tms) were obtained from the
inflection point of the data. For thermal denaturations of protein with palmitate (Sigma
Aldrich), 150 µM palmitate, from stock solution, and 50 µM protein was used.
Acrylodan labeling of mLTP variants
Proteins purified by Ni-NTA column were concentrated to 10-20 µM. 6-acryloyl-
2-(dimethylamino)naphthalene (acrylodan) was dissolved in acetonitrile and added to the
76
purified proteins in 10-fold excess concentration. The mixed sample was incubated at
4°C overnight.  All solutions containing acrylodan were protected from light. Precipitated
acrylodan and protein were removed by centrifugation and filtering through a 0.2 µm
nylon membrane Acrodisc syringe filters (Gelman Laboratory), and the soluble fraction
was concentrated. Unreacted acrylodan and protein impurities were removed by gel
filtration chromatography with phosphate buffer (50 mM sodium phosphate, 150 mM
sodium chloride, pH 7.5). The eluents were simultaneously monitored at 280 nm for
protein and 391 nm for acrylodan. Fractions were collected when absorbance was
observed at both 280 nm and 391 nm. The conjugation reaction looked to be complete, as
both absorbances overlapped for the only protein peak observed. Purified proteins were
verified by SDS-Page to be of sufficient purity, and MALDI-TOF analysis showed that
they correspond to the oxidized form of the proteins with acrylodan conjugated. Trypsin
digest analysis of acrylodan conjugated proteins showed that the acrylodan was attached
at the expected cysteine.
Fluorescence emission scan and ligand binding assay
Ligand binding was monitored by measuring the fluorescence emission of
protein-acrylodan conjugates with the addition of palmitate. Fluorescence measurements
were performed on a Photon Technology International Fluorometer equipped with a
stirrer at room temperature. Excitation wavelength was set to the excitation maximum for
each variant and measurements were taken at the wavelength of the emission maximum
for 30 – 60 sec at 2 nm intervals and 0.5 second integration time. Stock solution of
palmitate dissolved in ethanol was titrated into 2 ml of 500 – 1000 nM protein-acrylodan
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conjugate. The total amount of palmitate in ethanol was never allowed to exceed 1% of
the sample volume. The dissociation constants (Kd) were determined by fitting the
decrease in fluorescence to an equation for a non-cooperative binding model (Dubreil et
al. 1997).
Results and discussion
mLTP designs
mLTP contains four disulfide bridges: C4-C52, C14-C29, C30-C75, and C50-
C89. We used the ORBIT protein design software to design variants without each
disulfide bridge. Calculations were evaluated and five variants, C4H/C52A/N55E,
C4Q/C52A/N55S, C14A/C29S, C30A/C75A and C50A/C89E, were chosen (Figure 9).
The disulfide bridge C4-C52 anchors two helices to each other, with C52 more buried
than C4. In the final designs C4H/C52A/N55E and C4Q/C52A/N55S, the disulfide
bridge is lost, but residue 4 and 55 form an interhelical hydrogen bond, H4-E55 and Q4-
S55, with heavy atom distances of 2.8 Å. C14A/C29S gains a hydrogen bond between
S29 and S26. The C30-C75 disulfide bond is surrounded by nonpolar residues and both
residues are mutated to alanine in C30A/C75A mutant. C50-C89 anchors the C-terminal
loop to helix 3. The mutation C89E introduces hydrogen bonds with R47, S90 and K54.
Experimental validation
The circular dichroism wavelength scans of mLTP and the variants (Figure 10)
show that three of the five variants (C4H/C52A/N55E, C4Q/C52A/N55S and
C50A/C89E) have similar spectra to the wild type, with minima at 208 nm and 222 nm,
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characteristic of helical proteins. C14A/C29S and C30A/C75A, on the other hand, are not
folded properly, with wavelength spectra resembling those of ns-LTP with scrambled
disulfide bonds (Lin et al. 2004). In the mLTP crystal structure, C14-C29 and C30-C75
both link the end of helix 1 (residues 4-18) and helix 4 (residues 65-75), respectively, to
helix 2 (residues 27-39) near the narrow opening of the protein. The narrow opening was
suggested to have only limited flexibility by the low B-factor of the residues around it
(Shin et al. 1995). These observations plus our result that C14A/C29S and C30A/C75A
variants are unfolded imply the importance of these two disulfide bridges in anchoring
the molecule together. On the other hand, the two disulfides that were designed out
without a major change in the protein’s fold, C4-C52 and C50-C89, are connecting the N-
terminal and C-terminal region of the protein to helix 3 (residues 43-58) near the wide
opening of the protein. This opening is very flexible and is speculated to be a ligand entry
and exit site; thus, eliminating C4-C52 and C50-C89 disulfide bonds should be tolerated
better.
We determined the thermal stability of the variants in the absence and presence of
palmitate and compared it to wild-type mLTP (Figure 11). The removal of the disulfide
bridge C4-C52 significantly destabilizes the protein relative to the wild type, lowering the
Tm by as much as 28°C (Table 5). The disruption of C50-C89 leads to a Tm only 10°C
lower than that of the wild type. The variants are still able to bind palmitate, as evidenced
by the increase in the apparent melting temperatures when palmitate is present, as is
observed for the wild-type protein. The C4H/C52A/N55E and C4Q/C52A/N55S mutants’
thermodynamic behaviors were similar, since each variant supplied one potential
hydrogen bond to replace the disulfide bond. There was a much larger gain in stability
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upon binding palmitate for the two mutants above (~20°C) than was observed for the
wild-type protein (8°C), suggesting that these mutants might undergo a large
conformational change upon ligand binding. Therefore, they were predicted to be good
candidates for biosensor design. The difference in Tms between the palmitate-bound
mutants and wild type was 18°C, 10°C lower than the 28°C difference observed between
the unbound proteins. The deletion of disulfide bonds in the mutants decreased the
stability of the apo-protein far more than the complexed protein, confirming the idea that
it is highly likely these mutants show large conformational differences between the apo
and the complexed form, an important criterion in our biosensor design.
It is interesting that C50A/C89E is 15°C more stable than the C4-C52 variants.
The disulfide C50-C89 anchors the long C-terminal loop to helix 3. Disruption of this
disulfide only lowered the Tm by 10°C. This could be due to the three introduced
hydrogen bonds that were a direct result of the C89E mutation. The stability gained by
palmitate binding only raises the Tm by 6°C, similar to the 8°C observed for wild-type
mLTP.  For wild-type mLTP, the crystal and solution structures show little change in
conformation upon ligand binding (Shin et al. 1995; Gomar et al. 1996), and we suspect
this to be the case for C50A/C89E.
The C4-C52 mutated variants look promising as the basis for the development of
a reagentless biosensor. Fluorescent sensors are extremely sensitive to their environment.
By conjugating a sensor molecule to the site of conformational change, these mutants
could be used as a reporter for ligand binding.
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Protein-acrylodan conjugates
We chose two of the variants, C4H/C52A/N55E and C50A/C89E, and mutated
one of the original cysteine residues in each variant back. This did not disturb any of the
interactions we designed into the former disulfide bridge because all designed
interactions were not between the two residues constituting the disulfide bond. This gave
us four new variants: C52A, C4H/N55E, C50A, and C89E. We conjugated acrylodan
(Ac), an environment sensitive thiol-reactive fluorophore (Prendergast et al. 1983), to the
resulting free cysteine in each protein. Trypsin digest and tandem mass spectrometry of
C52A/C4-Ac confirmed that the acrylodan was conjugated to the correct cysteine.
Analytical ultracentrifugation of C52A/C4-Ac showed that it is a monomer (data not
shown), and all gel filtration profiles for all acrylodan-conjugated variants showed a
single dominant peak similar to C52A/C4-Ac, implying that all variants are monomers.
We obtained circular dichroism wavelength scans of the acrylodan-conjugated
variants to ensure they were properly folded (Figure 12). While all four conjugates
appeared folded with characteristic helical protein minima near 208 nm and 222 nm, the
C52A/C4-Ac spectra was closest to the wild-type mLTP spectra. Thermal denaturation
experiments (Table 5) show that when acrylodan is conjugated to C4 or C52, the apo-
protein stability is increased while the stability of the ligand bound protein is decreased,
compared to the C4H/C52A/N55E variant. For the mutants with the acrylodan conjugated
to C50 or C89, we see a different phenomenon in which the Tm of both the apo and ligand
bound form of the protein decrease or stay the same. This and additional data mentioned
below points to the possibility that acrylodan conjugated to C4 or C52 may fit into the
ligand-binding pocket of mLTP, stabilizing the apo-protein. When ligand is added, the
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acrylodan is displaced by the ligand; thus, the acrylodan will not induce any stabilizing
effect on the ligand-binding form of the protein. As mentioned below, the displacement
of the acrylodan by the ligand could also cause the fluorescence change observed with
ligand titration. This same mechanism has been suggested for the fluorescence change
that occurs upon ligand binding to acrylodan-conjugated intestinal fatty acid binding
protein (Richieri et al. 1992).
Ligand binding assays
We performed titrations of the protein-acrylodan conjugates with palmitate to test
the ability of the engineered mLTPs to act as biosensors. As predicted, of the four
protein-acrylodan conjugates, C52A/C4-Ac and C4H/N55E/C52-Ac show the most
marked difference in signal when palmitate is added (Figure 13A). For each titration, the
average of the fluorescence intensity time-based measurement at the emission maxima
(480nm) was used to fit a non-cooperative binding equation (Dubreil et al. 1997). We
determined the Kd of palmitate to be 0.6 µM for C52A/C4-Ac (Figure 13B) and 4 µM for
C4H/N55E/C52-Ac (Figure 13C). These values were close to the 3 µM Kd of palmitate to
wild-type LTP we measured using tyrosine fluorescence (Douliez et al. 2000).
We successfully engineered mLTP into a fluorescent reagentless biosensor for
nonpolar ligands. This was achieved using computational protein design to remove one of
the disulfide bridges and then attaching a thio-reactive fluorophore to the free cysteine.
We believe the observed change in acrylodan signal is a measure of the local
conformational change the protein variants undergo upon ligand binding, which causes
the displacement of the fluorophore from the hydrophobic binding pocket. The removal
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of the C4-C52 disulfide bridge provides the N-terminal helix more flexibility and allows
acrylodan to insert into the binding pocket.  Upon ligand binding, however, acrylodan is
displaced and shifts from an ordered nonpolar environment to a disordered polar
environment.  The observed decrease in fluorescence emission and the red shift of the
emission maxima as palmitate is added is consistent with this hypothesis.
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Table 5. Apparent Tms of mLTP and designed variants.
Apparent Tm
Protein alone
Protein +
Palmitate
ΔTm
mLTP 84 92 8
C4H/C52A/N55E 56 76 20
C4Q/C52A/N55S 56 74 18
C50A/C89E 74 80 6
C4H/ N55E/C52-Ac 62 71 9
C52A/C4-Ac 59 66 7
C50A/C89-Ac 64 73 9
C89E/ C50-Ac 71 80 9
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Figure 9. Ribbon diagram of mLTP and the designed variants of each disulfide. The
palmitate-bound mLTP (cyan) is superimposed on the unbound protein (green).
Palmitate is shown in spheres with carbon in magenta and oxygen in red. Disulfides are
in orange. In panels, mutated residues and the residues they form hydrogen bonds with
are shown in stick with CPK-inspired colors, and the modeled hydrogen bonds are shown
with yellow dashed lines, with measured heavy atom distances between 2.8 and 3.0 Å.
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Figure 10. Wavelength scans of mLTP and designed variants. Variants C4H/C52A/N55E
and C4Q/C52A/N55S and C50A/C89E are folded similar to wild-type mLTP, with
minima at 208nm and 222nm, but C14A/C29S and C30A/C75A are misfolded.
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Figure 11. Thermal denaturations of mLTP and designed variants: mLTP (red),
C4H/C52A/N55E (blue), C4Q/C52A/N55S (green), and C50A/C89E (cyan).  Solid lines
are protein alone, dashed lines are protein with palmitate added. Removal of disulfide
bridges significantly destabilized the protein, but the variants still bound palmitate.
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Figure 12. Circular dichroism wavelength scans of the four protein-acrylodan conjugates.
Each conjugate shows the characteristic minima near 208nm and 222nm for helical
proteins.  C52A/4C-Ac is most like wild-type mLTP.
94
95
Figure 13. Titration of C52A/C4-Ac with palmitate monitored by fluorescence emission.
(A) Fluorescence emission scans of C52A/4C-Ac (red) show decreased fluorescence with
addition of increasing concentrations of sodium palmitate. Only a subset of experimental
data is shown. Excitation wavelength is 363nm. Fluorescence monitored at 466nm was
used to determine the Kd. (B) C52A/C4-Ac Kd is 0.6 µM and (C) C4H/N55E/C52-Ac Kd
is 4 µM.
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Chapter 5 
 
Computational design and biochemical characterization 
of a solubility enhanced MW7 VH variant, an antibody 
variable domain fragment for huntingtin protein 
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Introduction 
Antibodies often play a key role in biological studies and have been widely used 
in the treatment of disease. By binding to specific antigens, antibodies can block 
interactions, tag target molecules, lock proteins into specific conformation, and even act 
as catalysts (Stocks 2004). However, due to their large size and the fact that antibodies 
naturally function in the extracellular space, their utility as therapeutics for intracellular 
targets has been limited. Recently, however, two major developments have allowed us to 
overcome these limitations. One is the application of recombinant DNA technology to 
engineer antibodies into smaller fragments that still retain their binding properties. 
Although all antibody domains serve a purpose, only the variable domain is necessary if 
binding is all that is desired. Fragments of whole antibodies have been engineered 
including the antigen binding fragment (Fab), the variable region fragment (Fv), single 
chain Fvs (scFv), single domains (VH or VL), and single loops. These smaller fragments 
also have the benefit of being able to be expressed in functional form in E. coli, making 
simple and large-scale production possible. Another major development is the discovery 
of antibodies that fold correctly and maintain their fold inside cells without the formation 
of disulfide bonds. Because the cytoplasm is strongly reductive, disulfide bonds cannot 
form in this environment. These intracellular antibodies, called intrabodies, are functional 
inside cells and are usually scFvs, but single antibody domains have also been 
successfully utilized. Many intrabodies related to human diseases, including AIDS, 
cancer, and various neurological disorders, have been isolated and studied (Lobato and 
Rabbitts 2004). The ability of intrabodies to modify the interior of cells provides a new 
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approach and affords them tremendous potential for use as therapeutics and biological 
reagents.  
Several intrabodies have been engineered that bind to exon 1 of huntingtin protein 
(htt), the mutant form of which is believed to cause neural toxicity in the striatum and 
cortex and result in Huntington’s disease (Lecerf et al. 2001; Khoshnan et al. 2002; Colby  
et al. 2004). One such intrabody is a scFv of the MW7 antibody, which recognizes the 
poly proline (polyP) domain of htt. When co-expressed with htt in 293 cells, MW7 scFv 
interferes with htt aggregation and decreases cell toxicity (Khoshnan et al. 2002). A 
similar response is also observed when only the VH of MW7 is expressed (P.H. Patterson, 
personal communication).  
We propose to design a highly soluble and stable mutant of MW7 VH using 
ORBIT (Optimization of Rotamers By Iterative Techniques), a computational protein 
design program developed by Stephen Mayo and co-workers. ORBIT predicts the 
optimal protein sequence for a given three-dimensional fold. It employs an unbiased, 
quantitative design algorithm based on a force field that includes van der Waals 
interactions, hydrogen bonding, solvation and electrostatic forces, and a discrete set of 
amino acid conformers called rotamers. Since MW7 VH is a small protein and we will 
only be considering a few positions for mutation, this problem is amenable to both 
computational design and extensive experimental manipulation and characterization. 
MW7 VH is functional when expressed in mammalian cells, but when expressed in E. 
coli, it aggregates and is not prone to refolding. Our objective is to use computational 
methods to predict mutations that will maintain binding to htt but will improve the 
solubility of the protein, allowing E. coli or baculovirus to be used for expression. After 
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expression and purification of the MW7 VH mutant molecules, we intend to assess 
functionality, biochemically characterize the active variants, and use X-ray 
crystallography to solve the structure of selected variants, alone and in complex with the 
polyP domain plus adjacent amino acid residues of htt.  
Currently, only three structures of engineered human VH exist in the PDB 
database, and no structures of antibodies that bind to htt are available, although one is to 
be published (P.J. Bjorkman, personal communication). An X-ray crystal structure of an 
MW7 VH mutant, especially with a ligand bound, will help elucidate the mechanism this 
antibody uses in preventing intracellular aggregation of htt. The crystal structure would 
also be useful in the computational design of an even more stable molecule. ORBIT 
employs the backbone of a crystal structure to predict mutations; since the crystal 
structure of MW7 VH is not available, we will initially utilize the backbone structure of 
the VH domain of an anti-breast tumor antibody, SM3 (PDB ID: 1SM3). Although the 
sequence identity of the VH domain of SM3 with MW7 VH is very high (86%), the 
backbone structures of the two probably differ. Using the actual structure should give 
more accurate results. Moreover, the crystal structure of MW7 VH with ligand bound can 
be used for affinity design. Thus, determining the ligand-bound structure of a MW7 VH 
variant will enhance the accuracy of our calculations and give us further opportunities to 
improve the stability and the binding for better treatments for Huntington’s disease.  
 
Materials and methods 
Expression of MW7 VH and variants in E. coli and baculovirus 
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The MW7 VH genes, with and without cysteines, with an N terminal flag tag 
cloned into pcDNA3.1 (Invitrogen) plasmid were obtained from Dr. Paul Patterson 
(California Institute of Technology). These genes were subcloned into pET-22b(+) 
(Novagen), which added a 6x-His tag on the C terminus, and pET-11a (Novagen) 
plasmids for E. coli expression. For baculovirus expression, the genes were cloned into 
the pAcGP67A vector (BD Biosciences) with a C terminal His tag to be used in 
purification. All variants were constructed by site-directed mutagenesis using inverse 
PCR. All E. coli expression was done using BL21 (DE3) cells (Stratagene). Cells were 
induced with isopropyl-β-D-thiogalactoside (IPTG) for three hours at 37°C. Inclusion 
bodies were solubilized in 7 M guanidine-HCl, 10 mM reduced glutathione and 1 mM 
oxidized glutathione. The proteins were refolded by a rapid dilution method in refolding 
buffer (100 mM Tris, 400 mM L-arginine pH 8.0). Refolded proteins were concentrated 
and purified by gel filtration chromatography using a Superdex 200 column (GE 
Healthcare) and Ni2+ affinity chromatography where applicable. All baculovirus 
expression was done by the Protein Expression Center, California Institute of 
Technology.  
 
Computational methods 
All variants were designed with the ORBIT protein design software (Dahiyat and 
Mayo 1996; Dahiyat et al. 1997; Dahiyat and Mayo 1997; Dahiyat and Mayo 1997; 
Street and Mayo 1998; Pierce et al. 2000). ORBIT predicts the optimal protein sequence 
for a given three-dimensional fold. Since a crystal structure of MW7 VH was not 
available, an alternative structure, 1SM3, was used for design. Details of the selection of 
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1SM3 will be explained in the Results and discussion section. Explicit hydrogens were 
added using MolProbity (Lovell et al. 2003) and the structure was energy minimized for 
fifty steps to remove any steric clashes. Solvation energies were calculated using the 
Lazaridis and Karplus method (Lazaridis and Karplus 1999).   
 
Coexpression of MW7 VH variants with 103-polyglutamine (polyQ) htt in cultured cells 
 293 cells were grown in DMEM supplemented with 10% heat-inactivated bovine 
serum and 2mM glutamine. Cells were grown to 70% confluence and co-transfected with 
12 µg of MW7 VH or variants cloned into pcDNA3.1 and 3 µg of htt exon 1, containing a 
103-residue Gln domain (polyQ) that was fused to EGFP using a calcium phosphate 
transfection method. The transfected cells were examined under the microscope after 48 
hours of incubation. 
 
Results and discussion 
Selection of backbone structure and design of MW7 VH variants 
The backbone structure to be used as the initial structure for ORBIT design, was 
chosen by searching the PDB database for antibody structures with very high sequence 
identity to MW7 VH. Other criteria were high resolution, preferably better than 2 Å, and 
the least number of gaps in the sequence when aligned with MW7 VH. A breast tumor 
specific antibody (SM3) structure (PDB ID: 1SM3) was the best candidate found (Figure 
14). Its VH domain sequence has 86% sequence identity to MW7 VH, its resolution is 1.95 
Å, and it has only one, single amino acid gap when the two sequences are aligned. 
Additionally, the epitope recognized by SM3 is the core repeating motif of epithelia 
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mucin, MUC1, which is rich in prolines (Dokurno et al. 1998). The fact that MW7 VH 
recognizes the polyP domain and SM3 binds to a proline rich motif indicated that the 
1SM3 structure would be a good candidate for MW7 VH modeling.  
Our design strategy was to design out the hydrophobic residues on the former VL 
interface of MW7 VH. Without a VL domain, these hydrophobic residues will be exposed 
to solvent and might destabilize MW7 VH. This is a common strategy used to stabilize 
single domains of antibodies.  Modifying the VH sequence so that it mimics camel VH 
domains, which occur naturally without light chains, or mass screening of antibody single 
domain libraries to find a molecule that is stable are the usual approaches (Ward et al. 
1989; Davies and Riechmann 1996; Wirtz and Steipe 1999; Tanaka et al. 2003; Colby et 
al. 2004). Our approach is to use computational protein design to replace these 
hydrophobic residues located in the interface region. Two methods were used to 
determine which hydrophobic residues to consider in the design. The first one employed 
ORBIT’s RESCLASS classification protocol in which the residue positions in the 
structure were assigned a core, boundary or surface classification based on the distance 
between the solvent accessible surface and the residue’s Cα and Cβ atoms (Dahiyat and 
Mayo 1997). The hydrophobic residues whose classification changed (from core to 
boundary, core to surface, or boundary to surface) when the VL domain of 1SM3 was 
removed were considered for the design. The second method included all hydrophobic 
residues on the VH domain within 5 Å of the VL domain. Since residues on the CDR are 
involved in antigen binding, they were excluded from the design. The first method 
selected Leu45, Trp47, Ile95, Tyr97 and Trp107 (Trp106 in MW7 VH) to be designed. 
The second method selected all the residues from the first method, plus Val37. Val37 was 
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classified as core by RESCLASS whether the VL domain was present or not. 
Nevertheless, it is located in the middle of the interface and is surrounded by the other 
residues considered in the design. When mutated to hydrophilic residues, the designed 
residues might not appreciate a hydrophobic residue poking out among them. Visual 
inspection of preliminary design calculation results showed that when Tyr97 is included 
in the design, it retains its current identity (because of an optimal hydrogen bond with 
Gln39), or is mutated into a residue that has poor contacts with neighboring residues. 
Thus, the identity of Tyr97 was retained in all subsequent designs. None of the residues 
selected for design was within 6 Å of the peptide antigen in the 1SM3 structure. Non-
selected residues that were within 10 Å of VL domain and classified as surface or 
boundary were allowed to change conformation, but not identity.  All other residues were 
fixed. 
ORBIT design results are as follows. Method 1 produced D1, which has L45R, 
W47K, I95T and W107E mutations. Method 2 produced D2, which has V37Q, L45R, 
W47K, I95T and W107E mutations. All the mutated residues showed extensive 
interactions with neighboring residues and with each other. Lys47 makes electrostatic 
contacts with Glu50, and to a lesser degree, with Asn35 (Figure 14B). Thr95 hydrogen 
bonds with Thr112 (Figure 14C) and Gln37, Arg45 and Glu107 make a salt 
bridge/hydrogen bond network with each other (Figure 14D). Previously, residues Leu45 
and Trp47 (with Gly44) on a VH molecule of human origin were mutated to Arg and Gly, 
respectively, successfully producing a soluble VH molecule (Davies and Riechmann 
1996). The fact that our methods selected both of these residues for our design and that 
one of our predicted mutations is the same (L45R) is an encouraging result. 
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Expression of MW7 VH and variants in E. coli 
 MW7 VH proteins, with and without cysteines, were expressed in a variety of E. 
coli strains including BL21 (DE3), BL21 (DE3) Lys, and Rosetta Blue. The amount of 
soluble protein expression did not differ between strains. MW7 VH expressed in inclusion 
bodies with no soluble proteins, and MW7 VH without cysteines expressed in soluble 
form in very small amounts; all subsequent expressions were therefore done in BL21 
(DE3) cells. Different plasmids, with and without His tag, were also tried with no 
significant difference. The refolding protocol described in the Materials and Methods 
section was used to refold MW7 VH and its variants. There were very few or no properly 
folded proteins after refolding. Using hydrogen deuterium exchange experiments by 
NMR, Pluckthun and co-workers showed that Ile95 on the heavy chain was highly 
protected during folding of an anti-phosphorylcholine scFv, implying that Ile95 might be 
important in initiating folding (Freund et al. 1996). Thus, a variant of D1 was made that 
did not include the I95T mutation. This molecule also expressed in inclusion bodies and 
was not prone to refolding. It is well known that VH domains often tend to form insoluble 
aggregates in the periplasm of E. coli. This might be because no general periplasmic 
chaperones are present to help the molecule with folding. Taking this and the fact that 
MW7 VH is functional in 293 cell culture into account, we decided to express MW7 VH 
and D1 in baculovirus, predicting that the chaperones in eukaryotic cells would assist in 
the proper folding of these molecules. This experiment is currently in progress; 
preliminary data indicates that both MW7 VH and D1 express in soluble form.  
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Expression of MW7 VH variants in 293 cells 
 To test for the functionality of MW7 VH variants in cell culture, 293 cells were 
co-transfected with MW7 VH with and without cysteines and its variants, with 103-polyQ 
htt fused to EGFP. It has been shown previously that MW7 VH, but not MW7 VH without 
cysteines, decreased htt aggregation and cell toxicity (P.H. Patterson, personal 
communication). Although the transfection data alone is insufficient to support any 
conclusions, it shows that the amount of transfected cells expressing htt is similar for 
MW7 scFv and D2 with and without cysteines. Our future work will include confirming 
whether the variants have functionality by analyzing the lysates of the transfected cells 
for aggregated htt with western blot using antibodies for htt and GFP. Staining the cells 
with flag and GFP antibody to observe the co-localization of MW7 VH variants with htt 
and TUNEL staining to show the degree of cell toxicity also need to be shown.   
 
Future directions 
 We have designed MW7 VH variants that are predicted to be more soluble and 
stable than MW7 VH. Preliminary data indicate that MW7 VH and its variant, D1, express 
solubly in baculovirus. These molecules will be purified using a Ni2+ affinity column and 
their stability will be measured by thermal and chemical denaturation using circular 
dichroism spectroscopy. The variant’s melting temperature and the free energy of folding 
will be compared to those of MW7 VH. The binding of the variants and MW7 VH will be 
initially determined by mixing the purified proteins with thioredoxin or GST fusion 
proteins of huntingtin exon 1 (TRX-HTT) containing normal length or expanded 
glutamines (Scherzinger et al. 1997; Bennett et al. 2002) then running a native gel or 
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using gel filtration chromatography. A more detailed binding study will be done with a 
BIACORE instrument to obtain the binding affinities. This system measures the surface 
plasmon resonance change that occurs when flowing analytes bind to ligands that are 
attached to a biosensor chip. TRX-HTT will be attached to CM5 biosensor chips using 
primary amine chemistry, and MW7 VH and its variants will be flowed over the sensor 
chip as previously described (P. Li, manuscript in preparation). Our final biochemical 
goal will be to crystallize MW7 VH or its variants with and without the polyP ligand and 
solve the structure by X-ray crystallography. Prior trials to crystallize anti-htt antibodies 
(MW1 Fab and Fv) with the polyQ ligand, a 10 – 15 residue peptide, were not successful 
(P. Li, manuscript in preparation). We will be attempting the same goal, but with a 
different system. PolyQ is notorious for being insoluble and aggregation prone, and the 
increased length of the polyQ domain is the direct cause for htt aggregation and leads to 
Huntington’s disease. On the other hand, polyP region is thought to confer structural 
stability to the N-terminal region of htt (Qin et al. 2004). Although polyP peptides are 
also insoluble, many proline rich peptides have been crystallized with their counterpart 
proteins. Also, the proline rich motif located between the polyP domains is soluble. 
Including a minimal polyP stretch with the proline rich motif might create a good 
candidate for co-crystallization with MW7 VH. Because the polyP domain does not 
directly cause htt aggregation, a variety of different peptides and fusion proteins that 
might improve its solubility can be tried as co-crystallization agents with MW7 VH. A 
pre-crystallization step is required to check if the peptides or fusion proteins for co-
crystallization actually bind to MW7 VH. The BIACORE assay mentioned above will be 
a good and simple validation method to determine binding. The polyP domain has the 
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potential to interact with proteins that have Src homology 3 (SH3) and WW domains. 
Recent research showed that the deletion of the polyP domain from htt reduced the 
number of cells with htt-labeled autophagic bodies that are known to contribute to cell 
death, and also reduced or eliminated amounts of vesicle trafficking proteins in htt bodies 
(Qin et al. 2004). This demonstrates the importance of the polyP domain in recruiting and 
sequestering cellular proteins in both normal and pathological cells. It also hints at the 
mechanism that MW7 uses to prevent cell toxicity in cell culture. Thus, solving the 
structure of the polyP domain bound to MW7 VH will be as important as, if not more 
important than solving the structure of MW7 VH bound to polyQ. The crystal structure of 
MW7 VH with its ligand will show the detailed molecular interaction between the two, 
giving us a more definitive picture of the mechanism.  
The functionality of the variants in cell culture should also be corroborated. 
Although the BIACORE binding assay will show us whether our designs bind to htt or 
not, the affinities of intrabodies measured in vitro do not necessarily correlate with their 
function in vivo (Tanaka and Rabbitts 2003). We have already observed that when the 
variants are tranfected into 293 cells, they do not cause any major toxicity to the cell or 
influence the expression of htt co-transfected with them (data not shown). As mentioned 
above, experiments that confirm the expression of the variants and determine whether 
they decrease htt aggregation should be performed; this can be done with western blot 
analysis. Immunohistochemical methods will be used to visualize the co-localization of 
htt and the variants, and TUNEL staining will be done to quantitate the reduction in cell 
toxicity.  
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The inability of our designed MW7 VH variants, D1 and D2, to be expressed as 
soluble protein in E. coli and to refold was disappointing. One explanation is that 
designing out the 4 to 5 hydrophobic residues we considered was not enough to solubilize 
the protein. Several hydrophobic residues located on the CDR at the interface were not 
considered for design, since we were concerned that altering these might disrupt the 
interaction between the antibody and the antigen. An alanine scanning analysis could be 
done to determine which hydrophobic residues on the CDR are not necessary for antigen 
binding. These residues could be additionally considered in future designs. Furthermore, 
Gly44 is another potential position to be considered. Previous attempts to camelise 
human VH were successful when residues 45, 47 and 44 were mutated to other residues 
(Davies and Riechmann 1996). One of the criteria we used to select residues for design 
was to require that they be hydrophobic. Even though residue 44 was chosen using both 
selection methods mentioned above, it was eliminated from the pool of residues 
considered because it was not hydrophobic.  
Another reason for the insolubility of the designed variants might be due to 
differences in the crystal structure used to model MW7 VH and the actual structure. 
Although SM3 has high sequence identity with MW7 VH and thus, was considered to be a 
good model, 1SM3 structure is of a Fab fragment, which includes not only VH, but VL, CH 
and CL domains. Comparison of the structure of a camelised VH with the structure of VH 
domain of Fv fragments from the same human VH family shows differences in certain 
parts of the backbone, especially at the interface (Riechmann 1996). By using the actual 
crystal structure of MW7 VH, this problem can be solved. Thus, the crystal structure of 
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MW7 VH can also be utilized in a second round of designs to produce variants with 
higher solubility and stability.   
Although all MW7 VH molecules mentioned were tested both with and without 
cysteines, the molecules without cysteines were not emphasized because they were not 
functional in cell culture (P.H. Patterson, personal communication). The reductive 
environment in the cytoplasm does not allow disulfide bonds to form; thus, we would 
expect similar functionality from both forms of MW7 VH. Removal of intra-domain 
disulphide bonds from intrabodies has been shown to have no substantial effect on in vivo 
expression or function (Tanaka et al. 2003). The contradictory results we observed with 
MW7 VH might be because the cysteine to alanine mutation used to delete cysteines did 
not result in optimal packing, which could destabilize the molecule. Packing is especially 
important in this case because the disulfide bond is deeply buried in the protein. In this 
sense, using ORBIT to design out the disulfide bonds should result in an optimal 
substitution for cysteines. ORBIT has been successfully used in the past to design out 
disulfide bonds (unpublished result) and repack protein cores (Dahiyat and Mayo 1997).  
Our ultimate goal in this project is to design a highly soluble and stable anti-htt 
polyP MW7 VH that could be used for a variety of applications.  These include use in 
yeast surface screening for antibodies with improved functionality (Colby et al. 2004), as 
bio reagents to detect htt, and as therapeutics for Huntington’s disease.   
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Figure 14. Structures of 1SM3 and its mutants showing the mutated residues (A) 
Structure of 1SM3 Fv. VH, VL, peptide ligand and CDR of VH is shown in cyan, gray, red 
and orange, respectively. The side chains of the residues mutated are shown. The wild-
type residues are shown in gold. (B) W47K (C) I95T (D) V37Q, L45R, W107E 
mutations in variant MW7 VH are shown in CPK-inspired colors.   
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Appendix A
Ab initio modeling and ligand binding study of
Edg4 and Edg6
The text of this chapter is adapted from the publication
Vaidehi N, Floriano WB, Trabanino R, Hall SE, Freddolino P, Choi EJ, Zamanakos G,
and Goddard WA 3rd. Proc Natl Acad Sci USA 2002 99, 12622-7.
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Abstract
We performed computational ab initio modeling and ligand docking studies of the
endothelial differentiation gene (Edg) G protein-coupled receptors Edg4 and Edg6. By
using a well-established molecular dynamics method, we derived atomic models for the
two receptors. The two receptors show different ligand specificities, with Edg4 binding to
lysophosphatidic acid and Edg6 binding to sphingosine-1-phosphate. Using these
molecules as positive agonists, we docked each of them to the predicted structure of each
of the receptors and found the most favorable binding site. Next, agonists and antagonists
were docked to the putative binding sites and the binding energies were calculated. The
results are consistent with experimental data.
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Introduction
Different extracellular stimuli transfer signals to the interior of the cell via
receptors on the cell surface. Many hormones, lipid mediators, oligopeptides, odorants
and taste molecules bind to G protein-coupled receptors (GPCRs) and induce their
conformational change, which initiates signal transduction in the cytoplasm. The GPCR
family is the largest known receptor family, comprising approximately 1% of the proteins
encoded by the humane genome (Sautel and Milligan 2000). The cellular mechanisms
that these diverse GPCRs are involved in are extremely important; hence, they are
frequently used as drug targets. The fact that over 50% of approved drugs are agonists or
antagonists of these receptors emphasizes their therapeutic significance (Gudermann et
al. 1995).
The use of molecular biology and comprehensive high throughput drug screening
has resulted in the discovery of many GPCR ligands, especially small molecule ligands of
peptide-binding GPCRs (Muller 2000). Nevertheless, ligand identification is difficult due
to the enormous number of possible ligands to be tested. Complications arising from the
elusive nature of certain ligands and cell assay systems with endogenous GPCRs make
the process more difficult (Marchese et al. 1999). In addition, even with the ligand
identified, a detailed understanding of ligand-receptor interactions is needed for drug
design and to gain insight into diseases caused by malfunction of the receptors. For these
reasons, structural and functional analysis of GPCRs is critical. Unfortunately, structural
information on GPCRs is insufficient. This problem can be overcome by using atomic
level models.
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The endothelial differentiation gene (Edg) receptor family is a subfamily of
rhodopsin-like GPCRs that has been implicated in diverse biological processes such as
cell proliferation, differentiation and migration (Lynch and Im 1999; Pyne and Pyne
2000). The most significant ligands for these receptors are sphingosine-1-phosphate
(S1P), a phosphorylated derivative of sphingosine that binds to Edg1, Edg3, Edg5, Edg6
and Edg8, and lysophosphatidic acid (LPA) that binds to Edg2, Edg4 and Edg7 (An et al.
1997a; An et al. 1997b; An et al. 1998; Lee et al. 1998; Im et al. 2000a; Im et al. 2000b;
Van Brocklyn et al. 2000). Edg receptors are widely distributed in many tissues and tend
to interact with multiple intracellular signal transduction pathways including MAPK,
phospholipase C/D, adenylate cyclase, JNK and small GTPases (Fukushima et al. 2001;
Takuwa et al. 2001). However, the biological functions and molecular mechanisms of
these receptors are poorly understood at the present time.
We modeled Edg6 and Edg4 using a computational GPCR tertiary structure
prediction method called MembStruk. Starting with these predicted structures, we then
used the HierDock ligand docking procedure to analyze receptor-ligand interactions
(Floriano et al. 2000). Edg6 was modeled because, in contrast to the universal distribution
of the majority of the Edg receptors, Edg6 expression is restricted to the tissues of the
immune system and thus, it is assigned important cell signaling roles in various immune
responses (Graler et al. 1998). Edg4 has ligand specificity opposite to Edg6 and was
selected because it has been implicated in ovarian cancer (Contos and Chun 2000; Fang
et al. 2002). The MembStruk/HierDock approach to modeling could be applied to find
ligands of receptors and to design ligands to be used as drugs. It could also be used to
assist in functional studies such as finding the site for mutagenesis studies, to understand
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the mechanism of ligand-receptor interactions, and to study the overall mechanism of the
receptor and its involvement in diseases.
Materials and methods
Prediction of Edg receptor structures by MembStruk
17 Edg receptor gene sequences were obtained by BLAST homology search
(Altschul et al. 1997) and used to obtain the sequence alignment profile by ClustalX
(Altschul et al. 1990). The transmembrane helices were identified on the basis of
hydrophobicity by the multi-sequence profile method (Donnelly 1993) implemented in
PERSCAN. A window size of 20 residues was used. The sequence for the Edg6 receptor
was used to build canonical right-handed helices with extended side chains. The
structures of these helices were optimized using the Newton-Euler Inverse Mass Operator
torsional MD method that scales linearly with the number of torsional degrees of freedom
(Jain et al. 1993; Mathiowetz et al. 1994; Vaidehi et al. 1996). This procedure fixes the
bonds and angles, optimizing the side chain conformations.
The orientation of each helical axis was determined using the bovine rhodopsin
7.5 Å electron density map (Schertler 1998). In addition, the hydrophobic moment of
each helix was directed outwards. The helices of Edg4 were rotated by running a coarse
grain rotation dynamics program called CoarseRot (Vaidehi et al. 2002). The helix
bundle was placed in the middle of a membrane bilayer composed of
dilauroylphosphatidyl choline, and the packing of the helix bundle was optimized using
rigid body dynamics. The DREIDING force field (Mayo et al. 1990) and CHARMM22
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(MacKerell et al. 1998) charges were utilized and the rigid body dynamics protocol was
run for 150 ps to attain equilibration.
Loops were then added to the helices with WHATIF software (Altenberg-
Greulich and Vriend 2001), and a molecular dynamics optimization was performed using
the MASSIVELY PARALLEL SIMULATION program (MPSim). (Ding et al. 1992a; b;
Lim et al. 1997) The procedure first optimizes loops with the helices fixed, then the entire
receptor is optimized.
Docking studies with HierDock
Each ligand was built in the extended conformation. The starting conformations
were optimized by potential energy minimization with the conjugate gradient method
employing the DREIDING force field (Mayo et al. 1990) and Gasteiger charges
(Gasteiger and Marsili 1980). The minimized conformations were used as starting
conformations for docking. The HierDock protocol (Floriano et al. 2000) and the
molecular surface of the protein model were used to locate the binding site using the
positive ligand. First, a coarse grain docking procedure using DOCK 4.0 (Ewing and
Kuntz 1997) was carried out. Void regions within the receptor are divided into several
boxes and multiple ligand conformations are sampled in them. Then, 1000 ligand
configurations are generated for each box and the 100 best scoring structures are kept.
Next, these best 100 ligand structures are minimized with the protein fixed using the
DREIDING force field and QEq charges. The structures are then ranked using both
energy and solvation. The binding site is defined as the site where most of the best
scoring ligands cluster. After defining the binding site, a library of ligands is docked to
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this binding region. The library docking procedure uses the protocol mentioned above,
plus another step in which the best structures (the top 10%) are further minimized with all
atoms movable. Then, each structure is scored and ranked using the binding energies,
which are calculated as the difference between the energy of the ligand in the receptor
and the energy of the free ligand.
Results and discussion
Structural model of Edg6 and Edg4 receptors
The seven helical transmembrane GPCRs of the Edg family are divided into two
subgroups according to the extent of amino acid sequence homology and ligand
specificity. The first group is selective for S1P and is comprised of Edg1, Edg3, Edg5,
Edg6 and Edg8 receptors. The second is selective for LPA, and includes Edg2, Edg4 and
Edg7. Using MembStruk and a proper description of the differential solvent environment,
we determined atomic level models of Edg6 and Edg4. No prior structural information
was used, except the receptor sequence and the 7.5 Å rhodopsin crystal structure, which
was used to align the helix axis (Figure 15).
Identification of the most probable binding site
Without any previous knowledge of the binding site, S1P and LPA were used as
positive ligands to find the putative binding sites for Edg6 and Edg4, respectively. The
binding site predicted by the HierDock protocol using the modeled structures was the
same for both receptors: between helix 3,5,6 and 7. This correlates well with the binding
region of the retinal in rhodopsin as well as the ligand-binding site in the cannabinoid
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receptor, which has the highest homology to the Edg receptors outside the Edg family
(Graler et al. 1998).
Binding affinity ordering
Having located the putative binding site, we docked S1P, LPA,
sphingosylphosphorylcholine (SPC) and 2-amino-2-[2-(4-octylphenyl)ethyl]-propane-
1,3-diol (FTY720) into the putative binding site and calculated the binding energies. SPC
has been reported to be a low affinity ligand for the S1P binding receptors with
approximately 10- to 100-fold lower activation. But this is controversial because
contradictory results have also been reported. Recently, it has been shown that activation
of Edg receptors by SPC might have been the result of contaminants or the indirect effect
of other SPC-specific GPCR (e.g., OGR1, G2A) activation (Van Brocklyn et al. 2000;
Fukushima et al. 2001; Kluk and Hla 2002; Xu 2002). FTY720 is an immunosuppressant
known to sequester lymphocytes in secondary lymphoid organs, thus decreasing the
number of patrolling lymphocytes, especially T lymphocytes (Brinkmann et al. 2000;
Brinkmann et al. 2001). Recently, the phosphate ester metabolite of FTY720 was found
to displace S1P binding with pico to nanomolar inhibitory concentration 50% (IC50)
values on S1P binding receptors (Mandala et al. 2002).
The binding energies from the docking results are listed in Table 6. The binding
energies of S1P and LPA for both receptors are consistent with the experimental results.
Edg6 prefers S1P to LPA, while Edg4 prefers LPA to S1P. The calculated binding energy
for Edg6 and SPC is worse than that for Edg6 and LPA, which does not correlate with
experimental results reported previously. But as mentioned above, this result is
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controversial. Our result supports the suggestion that SPC is at best a very weak ligand of
Edg receptors. Nevertheless, we cannot eliminate the possibility that the crudeness of the
model is reflected by this inconsistency with experimental data. Another explanation for
the bad binding energy obtained for SPC could be that SPC binds to Edg6, but at a
different binding site from S1P. Thus, docking SPC in the putative binding site located by
using S1P as a positive ligand might give a bad binding energy because the SPC binding
site is somewhere else. The calculation results for FTY720 show that it is a good ligand
for Edg6, with a binding energy close to the positive ligand S1P, while with Edg4, it has
a bad binding energy, close to that of S1P. This corroborates the assumption made in
prior publications in which FTY720 was hypothesized to be an Edg6 ligand because of its
immunosuppressant activity and its structural similarity with S1P,. This is further
substantiated by a recent report that the phosphate ester metabolite of FTY720 is a high
affinity agonist of at least four of the five S1P-specific Edg receptors.
Residues predicted as directly involved in binding the ligands
Figure 16 shows the predicted recognition site for Edg6 and Edg4 with the
residues involved in ligand binding displayed. The phosphate of S1P makes hydrogen
bonds with the Thr127 and Trp291 of Edg6, and the nitrogen of the ammonium group
makes a hydrogen bond with Glu284. On the other hand, Ser114 and Lys278 interact
with LPA in our model of Edg4. These residues are on helix 3 and 7, which correlates
with the helices in rhodopsin and the cannabinoid receptor interacting with each of their
own ligands.
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Not many site-directed mutagenesis studies have been done on the Edg receptors.
Homology modeling of Edg1 and Edg2 followed by experimental validation was
published recently (Parrill et al. 2000; Wang et al. 2001). These studies suggest that Edg1
uses Arg120, Arg292 and Glu121 to interact with S1P, while Edg2 uses Arg124 and
Lys304 to interact with LPA. The three residues our model predicts to interact with the
ligand in Edg6 differ from those reported for Edg1. Parrill and co-workers showed that
their three predicted ligand recognition residues are conserved in all S1P-binding Edg
receptors including Edg6. Our predicted residues are more than 5 Å away from their
prediction. This disagreement could be due to different S1P binding sites in different Edg
receptors. Different S1P-binding Edg receptors have different affinities and activity
responses to different agonists and antagonists; thus, it has been surmised that the binding
sites for each of the receptors may be different (Spiegel and Milstien 2000; Kluk and Hla
2002). Also, Edg6 is more likely to differ from the other S1P-binding Edg receptors
because it has relatively low sequence homology with them, and higher homology with
the LPA-binding Edg receptors. Thus, Edg6 is included in the S1P-binding Edg receptor
subfamily by its ligand specificity, but when considering only sequence homology, it
cannot be clearly grouped into either the S1P-binding or the LPA-binding subfamily
(Lynch and Im 1999; Van Brocklyn et al. 2000; Fukushima et al. 2001). Alignment of the
sequence for the human and the mouse Edg6 gene shows that Glu284 and the Trp291
residues are conserved, indicating that these residues are important and could indeed be
the residues utilized in ligand recognition.
In contrast to the results obtained with Edg6, the residues we predicted with our
Edg4 model correlate well with the results from the Parrill and co-workers. Lys278
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predicted by our model correlates with Lys304 of Edg2 when the two sequences are
aligned, and the Ser114 is conserved in all the LPA-binding receptors.
Conclusion
We used a modeling and docking protocol to predict the structures of two Edg
receptors and to dock predetermined ligands onto them. The docking study enabled us to
validate the modeling technique by allowing us to compare the computational results with
experimental results from the literature. It also allowed us to predict the receptor binding
site and putative ligands. During the procedure, the structural information used included
only the receptor sequences and the bovine rhodopsin crystal structure (for helix
alignment). Although the results achieved using these theoretical methods must be
validated experimentally, they are in good agreement with current published reports on
these receptors. This is certainly encouraging and accumulation of similar studies will lay
the foundation for theoretical modeling studies of proteins in the future.
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Table 6.  Computational binding energies of Edg6 and Edg4 to S1P, LPA, SPC and
FTY720.
Edg6 Edg4
S1P -41.7 -33.6
LPA -34.1 -40.6
SPC 33.4 39.2
FTY720 -40.3 -34.9
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Figure 15. Modeled structures of Edg6 (left) and Edg4 (right).
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 Figure 16. Predicted recognition site for Edg6 (A) and Edg4 (B) with the residues
involved in ligand binding displayed.
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A
Asn102
Tyr285
Thr127
Trp291
Glu284
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B
Lys278
Pro256
Ser114
Thr113
Trp169
